var title_f40_10_41120="Proposed DM model";
var content_f40_10_41120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Proposed model of dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 691px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69:2008. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41120=[""].join("\n");
var outline_f40_10_41120=null;
var title_f40_10_41121="Retained sponge of the breast on ultrasound";
var content_f40_10_41121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Retained sponge of the breast on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast sonogram shows hypoechoic mass with linear echogenic foci (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: pictorial review. AJR Am J Roentgenol 2009; 193:S94. Reprinted with permission from the American Journal of Roentgenology. Copyright &copy; 2009 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41121=[""].join("\n");
var outline_f40_10_41121=null;
var title_f40_10_41122="M mode echo mitral stenosis";
var content_f40_10_41122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis on M-mode echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top tracing shows a normal anterior mitral leaflet (AL), showing early opening (E) due to passive left ventricle filling and the late leaflet opening due to atrial contraction (A). The bottom tracing is from a patient with mitral stenosis. In contrast to the normal valve, the stenotic valve is thicker, as indicated by the multiple lines rather than a single one; it never closes during diastole and the slope of closure (E to F slope) is reduced with a velocity of 20mm/sec; and the posterior leaflet (PL) moves in parallel to the anterior rather than independently. In this patient the A wave is lost because of atrial fibrillation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41122=[""].join("\n");
var outline_f40_10_41122=null;
var title_f40_10_41123="CT traumatic EDH";
var content_f40_10_41123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TBI epidural hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan demonstrating a right epidural hematoma (EDH, arrow). Note the lenticular shape.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: J Claude Hemphill III, MD and Nicholas Phan, MD, FRCSC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41123=[""].join("\n");
var outline_f40_10_41123=null;
var title_f40_10_41124="Atovaquone and proguanil: Patient drug information";
var content_f40_10_41124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Atovaquone and proguanil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/902?source=see_link\">",
"     see \"Atovaquone and proguanil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/58/19365?source=see_link\">",
"     see \"Atovaquone and proguanil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Malarone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Malarone&reg;;",
"     </li>",
"     <li>",
"      Malarone&reg; Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat malaria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to atovaquone, proguanil, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug to stop malaria and have very bad kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other measures are needed along with this drug including using screens, bed netting, insect repellent (10% to 35% DEET), and permethrin spray on clothing and nets. Avoid spraying most insect repellents on children. Lower evening and night-time outdoor activity.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a pregnant woman and traveling to a malaria infested place, talk to your doctor about the risks first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever that happens while in or after coming back from the malaria area.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Start this drug before travel to the high risk place. Keep using after leaving.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696188",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told to stop malaria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up within 1 hour of taking this drug, take 1 more dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may crush the tablet and mix it with milk.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11069 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41124=[""].join("\n");
var outline_f40_10_41124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137595\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137596\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018470\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018472\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018471\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018476\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018477\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018479\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018474\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018475\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018480\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018481\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/902?source=related_link\">",
"      Atovaquone and proguanil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/58/19365?source=related_link\">",
"      Atovaquone and proguanil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_10_41125="Pathogenesis of bronchopulmonary dysplasia";
var content_f40_10_41125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Pathogenesis of bronchopulmonary dysplasia (BPD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exposure to antenatal pulmonary insults during the saccular state of lung development result in developmental arrest or delay in pulmonary maturation (\"new\" bronchopulmonary dysplasia [BPD]), whereas postnatal insults cause structural pulmonary injury (\"old\" BPD).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted&nbsp;from: Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357:1946.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41125=[""].join("\n");
var outline_f40_10_41125=null;
var title_f40_10_41126="Small nodules PA";
var content_f40_10_41126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small, rounded nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Standard ILO film for small rounded opacities, 3-10 mm in diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41126=[""].join("\n");
var outline_f40_10_41126=null;
var title_f40_10_41127="Transdermal contraceptive patch";
var content_f40_10_41127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transdermal contraceptive patch",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41127/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41127/contributors\">",
"     Ronald T Burkman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41127/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41127/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41127/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41127/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/10/41127/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits, risks, and contraindications of the transdermal contraceptive patch are generally similar to those of combined hormonal oral contraceptives. Both methods offer highly effective, reversible, noncoital-based contraception, but are subject to adverse estrogen-related side effects. However, transdermal hormonal contraceptive systems offer several potential advantages to oral contraceptive pills:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapeutic effects are achieved at lower peak doses since first-pass hepatic metabolism and enzymatic degradation in the gastrointestinal tract are avoided.",
"     </li>",
"     <li>",
"      Plasma hormone levels remain constant (peaks and troughs do not occur).",
"     </li>",
"     <li>",
"      Sustained drug delivery reduces the need for frequent self-administration, and thus may improve patient compliance.",
"     </li>",
"     <li>",
"      The nonoral route of administration is useful for patients who have difficulty swallowing pills.",
"     </li>",
"     <li>",
"      Immediate cessation of drug administration is possible with removal of the transdermal system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although data are limited, there is a possibility of an increased risk of venous thromboembolism (VTE) in patch users compared to users of estrogen-progestin oral contraceptives.",
"   </p>",
"   <p>",
"    Of note, the US Food and Drug Administration has issued a warning to providers and consumers about on-line sales of counterfeit contraceptive patches, as well as other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE AND PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transdermal contraceptive patch is a matrix system consisting of a thin 20 cm",
"    <sup>",
"     2",
"    </sup>",
"    square. It is composed of three layers: the outer layer is water-resistant and protects the underlying layer from the environment, the middle layer is medicated and adhesive, the inner layer is a clear release liner which is removed before patch application.",
"   </p>",
"   <p>",
"    The medicated layer contains two hormones, 0.75 mg of ethinyl estradiol (EE) and 6 mg of norelgestromin, the primary active metabolite of norgestimate. Approximately 20 mcg of EE and 150 mcg norelgestromin are released daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/2\">",
"     2",
"    </a>",
"    ]. The average overall ethinyl estradiol concentration (\"area under the curve\") in patch users is 60 percent higher than in women who use a 35 mcg ethinyl estradiol pill; however, peak ethinyl estradiol concentrations are 25 percent lower than in pill users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The area under the curve may be comparable to that of a 50 mcg ethinyl estradiol oral contraceptive pill.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All combined estrogen-progestin contraceptives (pill, patch, ring) have a similar contraceptive mechanism. The most important mechanism for providing contraception is",
"    <span class=\"nowrap\">",
"     estrogen/progestin-induced",
"    </span>",
"    inhibition of the midcycle surge of gonadotropin secretion so that ovulation does not occur. Another potential mechanism is suppression of gonadotropin secretion during the follicular phase of the cycle, thereby preventing follicular maturation. Progestin-related mechanisms also contribute to the contraceptive effect. These include changes in cervical mucus, fallopian tube motility, and endometrial receptivity that have unfavorable effects on fertilization and implantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women desiring a reversible, nonevent-based method of contraception who have no contraindications to use of estrogens or progestins constitute the initial population of potential users. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of contraception\", section on 'Choosing a method of contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to patch use are the same as those for other estrogen-progestin contraceptives (eg, history of thromboembolism, an estrogen dependent tumor, abnormal liver function). The World Health Organization and CDC have published medical eligibility criteria for use of hormonal contraceptives, including transdermal contraception (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with a history of sensitive skin or exfoliative dermatologic disorders may not be ideal candidates for using the patch.",
"   </p>",
"   <p>",
"    Women with skin hypersensitivity to any component of the transdermal system should not use this system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obese women should be counseled about the potential for reduced contraceptive efficacy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Efficacy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Effect of weight'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Screening requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening requirements are the same as for other estrogen-progestin hormonal contraceptives. Hormonal contraception can be safely provided after obtaining a thorough medical history and a blood pressure measurement. While breast examinations and screening for sexually transmitted diseases and cervical cancer are important, most experts agree that these procedures are not necessary before a first prescription for hormonal contraceptives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Screening requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manufacturer recommends that initiation of the patch occur on either the first day of menses (First Day Start) or the Sunday following the start of menses (Sunday Start). For the Sunday Start, back-up contraception (eg, condom, vaginal spermicide) should be used through the first seven days of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, the woman can start the patch at the time of her initial clinic visit (Quick Start), as long as pregnancy is reasonably excluded. A randomized trial comparing First Day Start to Quick Start found both approaches had continuation rates of about 90 percent after three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, patient preference should guide the method of initiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Extended cycle use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patch may be administered for extended cycles (an 'off-label\" use), although we avoid this practice, given the controversy about thrombosis risk in patch users. In the only study evaluating extended use of the transdermal contraceptive patch, 239 women were randomized in a 2:1 ratio to a standard (cyclic) or extended regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/6\">",
"     6",
"    </a>",
"    ]. The extended regimen was a weekly application of the patch for 12 consecutive weeks, followed by one patch-free week. After the patch-free week, users then completed three additional consecutive weekly applications.",
"   </p>",
"   <p>",
"    Compared to cyclic use, the extended regimen group had significantly fewer median bleeding days (14 versus 6), fewer bleeding episodes (one versus three), and fewer bleeding or spotting episodes (three versus two). However, the median numbers of bleeding or spotting days were similar for both groups (16 versus 14). In the extended use group, there was a significantly delayed median time to first bleeding (54 versus 25 days) and higher amenorrhea rates (12 versus 1 percent). Both regimens were associated with high user satisfaction rates (88.6 versus 86.3 percent), although there were more reports of headache, nausea, and breast discomfort in the extended regimen group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Applying and changing the patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patch is applied to the buttock, abdomen, upper arm, or upper torso (but not the breast, as it might cause breast tenderness due to high local estrogen concentration). A different site is used each time the new patch is applied. Lotions and occlusive dressings should not be used at patch application sites.",
"   </p>",
"   <p>",
"    The patch is changed once a week for three weeks (21 total days), followed by one week that is patch-free. It should always be",
"    <span class=\"nowrap\">",
"     changed/applied",
"    </span>",
"    on the same day of the week (eg, Sundays for Sunday start). Reminder systems are useful to ensure appropriate weekly changes. If a patient wants to switch to a new patch change day, this should be done during the last week of the cycle (ie, the patch-free week).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Delayed patch changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of failing to change the transdermal contraceptive patch at the appropriate time should be addressed with patients. The care provider should try various strategies to help users adhere to a schedule and thus avoid an unplanned pregnancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delay in beginning the first patch in a cycle &mdash; When a new patch cycle is delayed beyond the scheduled start day, users are instructed to apply a patch as soon as they remember and use backup contraception for at least one week. The day they apply the new patch becomes the new patch change day.",
"     </li>",
"     <li>",
"      Delay in beginning the second or third patch in a cycle &mdash; There is a two-day period of continued release of adequate contraceptive steroid levels when the patch is left on for two extra days. If users change the patch within this window, the patch change day remains the same and there is no need for backup contraception.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After this two-day time period, failure to replace the second or third patch in a cycle increases the risk for contraceptive failure. Therefore, users will need to use backup contraception or, in some instances, emergency contraception, if this occurs. The day the patient remembers to apply the patch becomes the new change day.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delay in removing the third patch in a cycle &mdash; Forgetting to remove the third patch on time carries less risk. The user is instructed to remove the patch when she remembers; the patch change day is not altered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Detached patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patch becomes partially or completely detached for less than 24 hours, it should be reapplied at the same location (if it has not lost its stickiness: ancillary adhesives or tape should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used), or replaced with a new patch immediately. If detachment lasts longer than 24 hours, a new patch should be applied, and this day of the week becomes the new patch change day. An additional method of contraception (condoms, spermicides) should be used for the first seven days of this cycle.",
"   </p>",
"   <p>",
"    In various trials, 1.8 percent of transdermal patches required replacement for complete detachment and 2.9 percent became partially detached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/7\">",
"     7",
"    </a>",
"    ]. Living in warm, humid climate did not increase the risk of detachment. The quality of adherence was illustrated in a study in which 30 women were subjected to various conditions over several seven-day time periods during transdermal patch use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/7\">",
"     7",
"    </a>",
"    ]. The conditions included normal activity, use of a sauna, immersion in a whirlpool bath, use of a treadmill followed by showering, cool water immersion, and a combination of these activities. Only one patch became detached during the 87 cycles that were evaluated, suggesting that skin adherence is not adversely affected by a vigorous, athletic lifestyle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal contraception is highly effective and as effective as oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/8\">",
"     8",
"    </a>",
"    ]. This was illustrated in three clinical trials that evaluated contraceptive efficacy in transdermal contraceptive patch users and oral contraceptive users; one trial was a noncomparative study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/9\">",
"     9",
"    </a>",
"    ], and two were randomized clinical trials (",
"    <a class=\"graphic graphic_table graphicRef77359 \" href=\"mobipreview.htm?41/6/42091\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Both the typical use and method use (perfect compliance with the dosing schedule) pregnancy rates were less than one pregnancy per 100 woman-years.",
"   </p>",
"   <p>",
"    The similarity between the typical and method patch use rates suggests that women in the trials were able to use the patch correctly without difficulty. This finding is supported by an analysis of self-reported rates of \"perfect\" compliance of patch users versus oral contraceptive users which showed that users of the transdermal contraceptive patch achieved perfect compliance more often than oral contraceptive users (88 versus 78 percent of cycles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/12\">",
"     12",
"    </a>",
"    ]. The rate of perfect compliance did not vary by age for patch users, while oral contraceptive users who were in younger age groups had lower perfect compliance rates.",
"   </p>",
"   <p>",
"    However, higher baseline body weight was associated with an increased risk of pregnancy. Five of the 15 pregnancies in the three clinical trials occurred among 83 women who weighed 90 kg (198 lbs) or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/13\">",
"     13",
"    </a>",
"    ]; this represented less than 3 percent of the overall study sample. The other 10 pregnancies were relatively evenly distributed across the range of weights below 90 kg in the study group. This finding is not unique to this method; women using the Norplant implant system weighing more than 160 lbs had higher contraceptive failure rates beginning at about three years of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, there is evidence among oral contraceptive users that higher body weight may carry an increased risk of contraceptive failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], but this is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Effect of weight'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NONCONTRACEPTIVE BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few data on potential noncontraceptive benefits of the transdermal contraceptive patch, users are likely to accrue the same benefits achieved by users of other types of estrogen-progestin contraceptives (eg, reduction in dysmenorrhea, iron deficiency anemia, and ovarian and endometrial cancer). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since patch use avoids intestinal absorption and the first pass effect through the liver, the patch is unlikely to impair the efficacy of other drugs (eg, some anticonvulsants and antibiotics), and its own efficacy is not affected by administration of other drugs given concomitantly. Support for this theory was provided by a study that reported serum levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/21/24921?source=see_link\">",
"     ethinyl estradiol-norelgestromin",
"    </a>",
"    were not affected when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    was administered to users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the manufacturer still warns that efficacy of the transdermal contraceptive patch may be affected by the use of some drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MAJOR ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both oral and transdermal estrogen containing contraceptives appear to have adverse effects on coagulation factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], placing users at increased risk of venous thromboembolism (VTE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/20\">",
"     20",
"    </a>",
"    ]. Based on the evidence described below (see",
"    <a class=\"local\" href=\"#H187360456\">",
"     'Thrombosis'",
"    </a>",
"    below), there may be a modest increased risk of VTE for patch users compared to users of current OCs; however, an increase has not been consistently demonstrated. Furthermore, the risk is far less than that encountered in pregnancy or the postpartum period.",
"   </p>",
"   <p>",
"    This potential risk should be balanced against the benefits of this method for preventing pregnancy in women who may not be able to use other methods successfully and against the absolute risk of symptomatic VTE in",
"    <span class=\"nowrap\">",
"     pregnancy/postpartum,",
"    </span>",
"    which is about 200 events per 100,000 pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The baseline incidence of venous thromboembolism in women of reproductive age has been estimated as 50 to 100 per 100,000 woman years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H187360456\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Data from epidemiological studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological studies by several groups have evaluated the risk of VTE, myocardial infarction, and stroke in contraceptive patch users compared to women using a norgestimate-containing 35 mcg EE oral contraceptive. A background document prepared for the FDA Advisory Committee for Reproductive Health Drugs concluded that &rdquo;none of the studies to date provides a definitive answer as to the safety of Ortho Evra with regard to thrombotic and thromboembolic events. The entire body of studies provides conflicting evidence that cannot be easily reconciled by considering any single difference among studies. Most of these studies have unique strengths and limitations, but the challenge lies in trying to reconcile multiple methodological differences between studies conducted in very different populations, often using different comparators and different exposure definitions&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/24\">",
"     24",
"    </a>",
"    ]. The FDA Advisory Committee indicated that for most patients, the benefits (ie, pregnancy protection) outweigh the risks of VTE since some women may not be able to successfully use oral contraceptives.",
"   </p>",
"   <p>",
"    It should be noted that VTE is a relatively rare event and has been reported as a potential risk of all hormonal contraceptive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14656600\">",
"    <span class=\"h4\">",
"     Boston collaborative drug surveillance program (BCDSP) data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jick and co-workers have published several studies using a variety of claims and databases to examine the risk of VTE among patch users compared with users of currently available oral contraceptives with varying results. Although two of their earlier studies showed no statistically significant increase in risk of VTE among patch users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], a more recent post-marketing study of 38 cases of VTE where the patch was compared to users of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    OC containing 30 mcg of ethinyl estradiol showed an OR of 2.41 (95% CI 1.17-4.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/27\">",
"     27",
"    </a>",
"    ]. When the group combined these new cases with the cases from their previous studies, the risk fell to a non-significant level:OR 1.23 (95% CI 0.86-1.77) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/28\">",
"     28",
"    </a>",
"    ]. A limitation of these studies is that ICD-9 coding was used to identify cases; there was no review of the medical records, which can reveal misclassification of subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14656607\">",
"    <span class=\"h4\">",
"     Other data",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An epidemiological study by another group also used insurance claims information and had a similar study design, except it included medical record verification of study outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/29\">",
"       29",
"      </a>",
"      ]. The objective of this study was to evaluate the risk of VTE, myocardial infarction and stroke among users of the contraceptive patch compared with users of norgestimate-containing oral contraceptives with 35 mcg of EE. For VTE, there were 152 total cases; 606 controls were matched to the cases by year of birth and index date of the case.",
"      <br/>",
"      <br/>",
"      The risk of VTE was significantly higher in current users of the patch compared with current users of the oral contraceptives, OR 2.2 (95% CI 1.2-4.0). The OR for stroke was 0.6 (95% CI 0.1&ndash;3.2), and for acute myocardial infarction was 1.2 (95% CI 0.3&ndash;4.7).",
"     </li>",
"     <li>",
"      A FDA sponsored study utilized computerized data files from two integrated medical care programs and two state Medicaid programs to obtain data regarding the risk of several cardiovascular endpoints in combined hormonal contraceptives users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/30\">",
"       30",
"      </a>",
"      ]. The authors identified 835,826 women who had at least one prescription filled for a combined hormonal contraceptive between 2001 and 2007. Outcomes evaluated included arterial thrombotic events ([ATE] myocardial infarction and ischemic stroke), VTE, cardiovascular disease mortality, and total mortality. The final cohort included 67,865 person-years of exposure to norelgestromin.",
"      <br/>",
"      <br/>",
"      In adjusted analyses of both current and new users, norelgestromin use was associated with a significantly higher risk of VTE relative to low-estrogen comparators (RR 1.55; 95% CI 1.17&ndash;2.07), particularly after 12 months of use (RR 3.05, 95% CI 1.23-7.53). When the analysis was restricted to new users, however, there was no increased risk. Because the risk of VTE is higher among new users of any combined hormonal contraceptive, and there were likely more new users in the norelgestromin group, the analysis combining current and new users probably underestimated the risk in the comparator group. To avoid this bias, comparisons should be made only among new users. In addition, although the authors attempted to adjust for some risk factors for VTE, they did not make adjustments for BMI, family history of VTE, or smoking, which are significant risk factors for VTE.",
"     </li>",
"     <li>",
"      A 15-year Danish historical cohort study evaluated data from national registries to determine the risk of arterial events, thrombotic stroke and myocardial infarction, in users of hormonal contraception compared with non-users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/31\">",
"       31",
"      </a>",
"      ]. The cohort included the entire population of Danish women, 15 to 49 years of age, for the period 1995 through 2009. During 4748 person years of contraceptive patch use, two thrombotic strokes (incidence",
"      <span class=\"nowrap\">",
"       42/100,000",
"      </span>",
"      person years; adjusted RR 3.13, 95% CI 0.79-12.60) and no myocardial infarctions were observed. Among nonusers, the incidence of thrombotic stroke and myocardial infarction were",
"      <span class=\"nowrap\">",
"       24.2/100,000",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       13.2/100,000",
"      </span>",
"      person years, respectively. Given that there were only 4748 person-years of observation for patch users with a wide confidence interval crossing 1.0, it is unclear whether the observed trend in stroke risk represents a real difference compared with nonusers. The risk was comparable to the risk with use of all other estrogen-progestin contraceptives. Therefore, although the risk of arterial events in patch users may be increased compared with women not using hormonal contraception, the absolute risk is likely very small, and probably would be acceptable to most women given the contraceptive and noncontraceptive benefits of hormonal contraception.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Effect on coagulation factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other studies have attempted to determine whether the contraceptive patch and oral contraceptives have different effects on",
"    <span class=\"nowrap\">",
"     serum/plasma",
"    </span>",
"    markers of thrombosis. Two randomized trials found that both the contraceptive patch and various oral contraceptives produced similar prothrombotic changes in several putative markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], while one small trial reported that the contraceptive patch and contraceptive vaginal ring produced more adverse changes on levels of protein C than did an oral contraceptive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that differences in the effects on prothrombotic markers do not necessarily predict differences in risk of clinical thrombotic events either in populations of women or in individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently reported side effects (other than unscheduled bleeding) in clinical trials of the transdermal patch were breast symptoms (22 percent), headache (21 percent), application site reactions (17 percent), nausea (17 percent), upper respiratory tract infection (10 percent), and dysmenorrhea (10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/33\">",
"     33",
"    </a>",
"    ]. Fewer than 2 percent of women considered any of these side effects a reason to discontinue the method. For trials comparing the patch to an oral contraceptive, the frequency of these side effects was similar except that patch users had application site reactions, more breast symptoms (only during the first two cycles), and more dysmenorrhea. About 85 percent of women experiencing breast symptoms described them as mild to moderate; the frequency declined markedly with continued use of the method.",
"   </p>",
"   <p>",
"    The pattern of breakthrough bleeding (bleeding requiring more than one pad or tampon daily) and spotting with the transdermal contraceptive patch is similar to that reported in oral contraceptive trials. As indicated in the table (",
"    <a class=\"graphic graphic_table graphicRef64067 \" href=\"mobipreview.htm?24/31/25084\">",
"     table 3",
"    </a>",
"    ), by about six months, the frequency of such bleeding declines substantially and remains stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A placebo-controlled, randomized trial found no evidence that use of the patch affected body weight over nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/33\">",
"     33",
"    </a>",
"    ]. Mean body weight increased from baseline by less than two pounds for both the contraceptive patch and placebo groups, with 80 percent of users in both groups within 5 percent of their starting weights by the end of nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with the patch increases sex hormone binding globulin (SHBG) more than observed in pill users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/4\">",
"     4",
"    </a>",
"    ], but the reduction in androgen levels is comparable to that with oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41127/abstract/35\">",
"     35",
"    </a>",
"    ]. In one study, the mean increase in SHBG from baseline after three cycles of treatment with the patch or pill was 449 and 274 percent, respectively; free testosterone fell 60 and 59 percent, respectively, and DHEAS fell 26 and 32 percent, respectively. Thus, the patch is likely to be useful in treatment of disorders associated with androgen excess (eg, acne, hirsutism). Of note, when lower doses of estrogen are administered transdermally (eg, postmenopausal hormone therapy), no significant increase in SHBG is observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2061483\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two new contraceptive patches are currently being studied. One contains ethinyl estradiol and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    . The daily delivery of estrogen by this patch is less than that delivered by the current patch and comparable to a 30-mg ethinyl estradiol pill. A progestin-only patch containing levonorgestrel is also under development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=see_link\">",
"       \"Patient information: Choosing birth control (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"       \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"       \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefits, risks, and contraindications of the transdermal contraceptive patch are similar to those with combined hormonal oral contraceptives, except the patch may be associated with more estrogen-related adverse events. However, the patch has the benefit of convenience of weekly administration, which generally appears to improve compliance. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The transdermal contraceptive system is a matrix system consisting of a thin 20 cm2 square patch. The medicated layer contains 0.75 mg of ethinyl estradiol (EE) and 6 mg of norelgestromin. Approximately 20 mcg of EE and 150 mc norelgestromin are released daily. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Structure and pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patch is generally applied weekly for three consecutive weeks, followed by a patch-free week. It can be applied to the buttock, abdomen, upper arm, or upper torso (but not the breast, as it might cause breast tenderness due to high local estrogen concentration). A different site should be used each time a new patch is applied. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a patch is not changed at the appropriate time, backup contraception may be needed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Delayed patch changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a patch is detached for less than 24 hours, it can be reapplied at the same location or replaced with a new patch immediately. If detachment last longer than 24 hours, a new patch should be applied. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Detached patch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a possibility of an increased risk of venous thromboembolism in patch users compared to users of combined oral contraceptives. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Major adverse events'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     U.S. Food and Drug Administration. Combating Counterfeit Drugs. www.fda.gov/oc/initiatives/counterfeit/. (Accessed January 4, 2008).",
"    </li>",
"    <li>",
"     Ortho Evra (norelgestromin/ethinyl estradiol transdermal system). Product labeling. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc, Revised September 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/3\">",
"      van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/4\">",
"      Devineni D, Skee D, Vaccaro N, et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol 2007; 47:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/5\">",
"      Abrams LS, Skee DM, Natarajan J, et al. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J Clin Pharmacol 2001; 41:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/6\">",
"      Stewart FH, Kaunitz AM, Laguardia KD, et al. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol 2005; 105:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/7\">",
"      Zacur HA, Hedon B, Mansour D, et al. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2002; 77:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/8\">",
"      Gallo MF, Grimes DA, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2003; :CD003552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/9\">",
"      Hedon, B, Helmerhorst, FM, Cronje, HS, Shangold, G, et al. Comparison of efficacy, cycle control, compliance, and safety in users of a contraceptive patch versus an oral contraceptive. BJOG 2000; 70:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/10\">",
"      Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/11\">",
"      Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/12\">",
"      Archer DF, Bigrigg A, Smallwood GH, et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002; 77:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/13\">",
"      Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/14\">",
"      Gu S, Sivin I, Du M, et al. Effectiveness of Norplant implants through seven years: a large-scale study in China. Contraception 1995; 52:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/15\">",
"      Burkman RT, Fisher AC, Wan GJ, et al. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009; 79:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/16\">",
"      Society of Family Planning, Higginbotham S. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091. Contraception 2009; 80:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/17\">",
"      Abrams, LS, Skee, D, Natarajan, J, et al. Tetracycline HCL does not affect the pharmacokinetics of a contraceptive patch. Int J Gynecol Obstet 2000; 70:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/18\">",
"      Johnson JV, Lowell J, Badger GJ, et al. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 2008; 111:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/19\">",
"      Kluft C, Meijer P, LaGuardia KD, Fisher AC. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception 2008; 77:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/20\">",
"      Douketis JD, Ginsberg JS, Holbrook A, et al. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997; 157:1522.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin 19, ACOG, Washington DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/22\">",
"      Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/23\">",
"      Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75:328.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Background Document for Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management. Advisory Committee. NDA 21-180 Ortho Evra. www.fda.gov (Accessed on January 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/25\">",
"      Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006; 73:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/26\">",
"      Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2007; 76:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/27\">",
"      Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010; 81:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/28\">",
"      Jick SS, Hagberg KW, Kaye JA. ORTHO EVRA and venous thromboembolism: an update. Contraception 2010; 81:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/29\">",
"      Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010; 81:408.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. file://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf (Accessed on February 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/31\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/32\">",
"      Fleischer K, van Vliet HA, Rosendaal FR, et al. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res 2009; 123:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/33\">",
"      Sibai BM, Odlind V, Meador ML, et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002; 77:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/34\">",
"      Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007; 197:134.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41127/abstract/35\">",
"      White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 2005; 192:2055.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5425 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41127=[""].join("\n");
var outline_f40_10_41127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE AND PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Screening requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Extended cycle use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Applying and changing the patch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Delayed patch changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Detached patch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NONCONTRACEPTIVE BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MAJOR ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H187360456\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Data from epidemiological studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14656600\">",
"      Boston collaborative drug surveillance program (BCDSP) data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14656607\">",
"      Other data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Effect on coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2061483\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5425|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 1\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/6/42091\" title=\"table 2\">",
"      Patch efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/31/25084\" title=\"table 3\">",
"      Patch breakthru bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_10_41128="Approach to HIV-infected patients with central nervous system lesions";
var content_f40_10_41128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to HIV-infected patients with central nervous system lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41128/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41128/contributors\">",
"     Igor J Koralnik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41128/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41128/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/10/41128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and management of the HIV-infected patient who presents with a change in mental status or abnormal neurologic examination is a challenging problem. Patients often have lesions on computed tomography (CT) scan or magnetic resonance imaging (MRI), which may represent life-threatening emergencies depending upon their size and location.",
"   </p>",
"   <p>",
"    The most important factor in determining the differential diagnosis is the degree of immunosuppression in the host.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with CD4 cell counts",
"      <span class=\"nowrap\">",
"       &gt;500/microL,",
"      </span>",
"      benign and malignant brain tumors and metastases predominate, as in immunocompetent hosts.",
"     </li>",
"     <li>",
"      In moderately immunosuppressed patients with CD4 cell counts from 200 to",
"      <span class=\"nowrap\">",
"       500/microL,",
"      </span>",
"      HIV-associated cognitive and motor disorders are common, but usually do not present with focal lesions.",
"     </li>",
"     <li>",
"      CNS mass lesions are most common in severely immunosuppressed patients with CD4 cell counts",
"      <span class=\"nowrap\">",
"       &lt;200/microL.",
"      </span>",
"      The most likely diagnostic considerations include opportunistic infections (OIs) and AIDS-associated tumors, such as primary central nervous system lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, multiple etiologies can coexist in an immunosuppressed individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In one study of HIV-infected patients undergoing brain biopsy for the diagnosis of focal CNS lesions, 6 percent had more than one etiology established from histologic sampling of a single lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough knowledge of the various etiologies for CNS disease in the HIV-infected patient is important for proper evaluation and management. The leading diagnostic considerations in a patient with advanced immunosuppression are Toxoplasma encephalitis, primary CNS lymphoma, progressive multifocal leukoencephalopathy, HIV encephalopathy, and CMV encephalitis.",
"   </p>",
"   <p>",
"    Patients who are not under medical supervision, or those who are not aware of their HIV status, may present with their first opportunistic infection in the central nervous system. The clinical manifestations and the diagnostic possibilities are similar to those seen in the pre-HAART era.",
"   </p>",
"   <p>",
"    However, the effect of prophylaxis for Pneumocystis and the use of HAART may alter the clinical spectrum of disease and the diagnostic considerations in patients who are taking medications. Although the list of etiologies is essentially the same, the incidence and the spectrum of disease has changed as illustrated by the following points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of TMP-SMX prophylaxis against Pneumocystis is also effective for the prevention of TE. In one study, the frequency of TE decreased from 72.2 to 18.6 percent from 1991 to 1996 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The introduction of HAART has been associated with a declining incidence of HIV encephalopathy, primary CNS lymphoma, and progressive multifocal encephalopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. On the other hand, it is possible that HAART may be contributing to a new form of severe, demyelinating leukoencephalopathy characterized by intense perivascular infiltration by HIV antigens and inflammatory cells with widespread myelin loss and axonal injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RADIOLOGIC APPEARANCE OF CNS LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of a CNS lesion is made by head CT or MRI. These examinations must be performed before and after injection of contrast material to determine whether a lesion enhances on neuroimaging. Enhancement usually signifies the presence of inflammation. Clinicians need to be aware that steroid therapy, which reduces inflammatory responses, can convert enhancing into nonenhancing lesions. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Corticosteroids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    MRI has a number of advantages compared to CT scan. It is much more sensitive than CT scan in determining if a lesion is truly solitary; it has greater sensitivity for white matter disease or lesions in the posterior fossa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/7\">",
"     7",
"    </a>",
"    ]; and, if a biopsy is being considered, it may identify a peripheral lesion that is more accessible for histologic sampling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/8\">",
"     8",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74958 \" href=\"mobipreview.htm?36/45/37588\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CNS mass lesions can be classified into two categories, according to the presence or absence of mass effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CNS lesions with mass effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS mass lesions are characterized by the presence of swelling, edema, and mass effect on surrounding structures. In some cases, especially for lesions located in the posterior fossa, cerebral herniation occurs. Mass lesions usually enhance after the injection of contrast material, indicating local inflammation and breakdown of the blood-brain barrier.",
"   </p>",
"   <p>",
"    Patients with mass effect can present with headache, nausea, vomiting, confusion, and lethargy, all of which may reflect evidence of increased intracranial pressure.",
"   </p>",
"   <p>",
"    The two leading diagnoses associated with mass effect in developed countries are Toxoplasma encephalitis and primary central system lymphoma. In the developing world, tuberculomas are a leading diagnostic consideration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Toxoplasma encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma encephalitis (TE) represents reactivation disease from prior infection. Affected patients present with fever, headache, altered mental status, and focal neurologic complaints or seizures. Supporting laboratory findings include the presence of Toxoplasma antibodies, which is consistent with past exposure, and advanced immunosuppression with CD4 counts &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TE lesions are generally multiple and are localized in the parietal or frontal lobes, in the thalamus or basal ganglia, or at the cortico-medullary junction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/10\">",
"     10",
"    </a>",
"    ]. Ring enhancement is present in approximately 90 percent and surrounding edema with mass effect is often seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74466 \" href=\"mobipreview.htm?27/9/27792\">",
"     image 2",
"    </a>",
"    ). Uncommonly, TE can present as a diffuse encephalitis, which is not associated with focal abscess formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neuroradiologic characteristics of TE are not pathognomonic and may be observed in other conditions, particularly lymphoma. If a single lesion is seen, an MRI should be obtained to determine whether the lesion is truly solitary. Although single lesions can be seen in TE infection, solitary large (&gt;4 cm) lesions are more suspicious for primary CNS lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Primary central nervous system lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary central nervous system lymphoma (PCNSL) can present with confusion, lethargy, memory loss, hemiparesis, aphasia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures. In addition, constitutional symptoms, such as fever, night sweats, and weight loss, occur in over 80 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to patients with toxoplasmosis, solitary and multiple mass lesions occur with approximately equal frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The majority of lesions display some degree of enhancement that is irregular or patchy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68209 \" href=\"mobipreview.htm?2/59/2992\">",
"     image 3",
"    </a>",
"    ). However, diffuse ring enhancement, identical to that commonly seen in TE, can occur.",
"   </p>",
"   <p>",
"    The location and size may also be helpful to distinguish Toxoplasma infection from PCNSL. As an example, lesions that involve the corpus callosum or the periventricular or periependymal areas are more likely to be due to PCNSL, whereas posterior fossa lesions are more likely due to infection. Lesions that are larger than 4 cm in size are more likely to be lymphoma. However, these neuroradiologic characteristics do not discriminate well enough between TE and PCNSL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other opportunistic infections can be associated with focal CNS lesions with or without mass effect, depending upon their size and location. These include brain abscesses secondary to Staphylococcus, Streptococcus, Salmonella, Aspergillus, Nocardia, Rhodococcus, Listeria, unusual granulomatous collections, such as cryptococcomas, and syphilitic gummas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. However, most of these entities are much less common than TE or PCNSL and are often associated with evidence of disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the developing world, neurocysticercosis or tuberculosis can present as single or multiple mass lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/9\">",
"     9",
"    </a>",
"    ]. The appearance of neurocysticercosis depends upon the stage of the infection and the host immune response. Tuberculomas can present as a focal lesion without evidence of systemic illness or meningeal infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28232?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cysticercosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28713?source=see_link&amp;anchor=H18643126#H18643126\">",
"     \"Central nervous system tuberculosis\", section on 'Tuberculoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     CNS lesions without mass effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions without mass effect usually do not enhance after the injection of contrast material and are not associated with a risk of herniation. The vast majority of these lesions are due to progressive multifocal leukoencephalopathy or HIV-associated encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Progressive multifocal leukoencephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease caused by the JC virus, a papovavirus that can be reactivated in the setting of severe immunosuppression. Patients with PML characteristically present with rapidly progressive focal neurologic deficits including hemiparesis, visual field deficits, ataxia, aphasia, and cognitive impairment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PML is usually characterized by multifocal areas of demyelination that are bilateral, asymmetric, and localized preferentially to the periventricular areas and the subcortical white matter. The lesions are generally not contrast-enhancing and are not surrounded by edema; as a result, substantial mass effect on surrounding structures is absent. However, PML may occur in the setting of an immune reconstitution inflammatory syndrome (IRIS) associated with increase of CD4+ T cell count and drop of HIV plasma viral load on HAART. In this context,",
"    <span class=\"nowrap\">",
"     PML/IRIS",
"    </span>",
"    can present with contrast enhancement on MRI, as well as focal edema and mass effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed discussion of the appearance of PML on CT and MRI imaging is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of PML includes HIV encephalopathy, cytomegalovirus encephalitis, and PCNSL. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     HIV encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV encephalopathy (HIVE) typically presents with the classic triad of symptoms of subcortical dementia: memory and psychomotor speed impairment, depressive symptoms, and movement disorders. Although this entity is not usually included in the category of CNS mass lesions, it can masquerade as PML. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12249?source=see_link\">",
"     \"Dementia and delirium in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On MRI, multiple hyperintense signals are seen in T2-weighted images, which are generally non-enhancing and localized bilaterally in the subcortical white matter (",
"    <a class=\"graphic graphic_picture graphicRef82180 \" href=\"mobipreview.htm?31/17/32016\">",
"     image 4",
"    </a>",
"    ). In contrast to the findings seen with PML, HIVE lesions are usually symmetrical and less well-demarcated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cytomegalovirus encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalitis due to cytomegalovirus (CMV) results from reactivation in patients with CD4 cell counts below 50",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    These patients present with delirium, confusion, and focal neurologic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7623?source=see_link\">",
"     \"AIDS-related cytomegalovirus neurologic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI can show either diffuse micronodular encephalitis or ventriculoencephalitis. The former is characterized by multifocal, diffusely scattered micronodules widely distributed in the cortex, basal ganglia, brainstem, and cerebellum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/22\">",
"     22",
"    </a>",
"    ], while ventriculoencephalitis is characterized by progressive ventricular enlargement, periventricular enhancement, and increased periventricular signal on T2-weighted images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/23\">",
"     23",
"    </a>",
"    ]. Rarely, CMV causes focal ring-enhancing lesions with edema and mass effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ancillary imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and",
"    <span class=\"nowrap\">",
"     MRI/CT",
"    </span>",
"    criteria alone are insufficient to lead to a diagnosis or to direct appropriate treatment in HIV-infected patients with CNS lesions. As a result, a variety of specialized imaging studies have been investigated, including thallium SPECT scans, perfusion MRI, MR spectroscopy, and positron emission tomography.",
"   </p>",
"   <p>",
"    These techniques are more sensitive than specific, and they may not be readily available outside of large academic institutions. Thus, their role in helping the clinician establish the cause of a CNS lesion is unclear.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thallium 201 SPECT scan has been used to help differentiate CNS lymphoma from CNS toxoplasmosis, since thallium is more avidly taken up to tumor cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/25-29\">",
"       25-29",
"      </a>",
"      ]. In a study of 37 AIDS patients with intracranial mass lesions on CT or MRI, all 12 patients with increased isotope uptake had biopsy proven PCNSL, while 24 of 25 without uptake had TE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perfusion MRI has been assessed to determine if changes in cerebral blood flow to CNS lesions can help distinguish TE from PCNSL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/30\">",
"       30",
"      </a>",
"      ]. This imaging modality demonstrated decreased local blood flow in five patients with TE; in contrast six patients with lymphoma had increased flow. Reduced perfusion in TE may be related to lack of vasculature within an abscess compared to the relative hypervascularity of tumor tissue.",
"     </li>",
"     <li>",
"      The utility of MR spectroscopy was assessed in 60 HIV-seropositive patients (25 with HIVE, 20 with TE, 8 with PML and 7 with PCNSL) and 22 HIV-seronegative controls. MRS demonstrated a high sensitivity in detecting intracranial pathology, but poor sensitivity in the differential of CNS disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positron emission tomography (PET) also may help differentiate PCNSL from CNS toxoplasmosis, as demonstrated in two small studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach that we usually follow is summarized in the following algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef50593 \" href=\"mobipreview.htm?22/7/22655\">",
"     algorithm 1",
"    </a>",
"    ). However, the algorithm is not as applicable in developing countries where alternative strategies need to be considered that take into account tuberculosis as a common cause of CNS mass lesions as well as any limitations in the availability of diagnostic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     CSF examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture is contraindicated in patients with focal signs or with lesions producing mass effect, especially in the posterior fossa, due to the risk of transtentorial herniation. If the patient does not have any focality on examination and mass effect is not evident, then consideration should be given to cerebrospinal fluid (CSF) examination, although its utility is limited.",
"   </p>",
"   <p>",
"    In patients with TE, PML, or PCNSL, CSF analysis may demonstrate a mild pleocytosis and elevated protein concentration, which are nonspecific. CSF cytology can help in the diagnosis of lymphoma if it is positive, but this occurs in only 15 percent of cases with meningeal seeding. Cultures that are performed for isolated abscesses are often negative.",
"   </p>",
"   <p>",
"    The CSF findings in patients with brain abscess usually reflect a parameningeal pattern with &lt;500",
"    <span class=\"nowrap\">",
"     leukocytes/microL",
"    </span>",
"    (predominantly lymphocytes), a normal glucose concentration, and a normal to mildly elevated protein concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link&amp;anchor=H12#H12\">",
"     \"Toxoplasmosis in HIV-infected patients\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38104?source=see_link&amp;anchor=H18#H18\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\", section on 'Lumbar puncture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) analysis may assist in identifying the DNA of JC virus (the causative agent of PML), Epstein-Barr virus (associated with PCNSL), and Toxoplasma gondii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14,35\">",
"     14,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCR detection of JC virus DNA in PML had a sensitivity of 74 to 93 percent and a specificity of 92 to 100 percent before the era of HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14,36-44\">",
"     14,36-44",
"    </a>",
"    ]. Since then, the sensitivity of this test has dropped to 58 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This is likely explained by HAART-induced immune recovery, which may lower JCV replication below the level of assay detection.",
"   </p>",
"   <p>",
"    A patient with a positive PCR result who has a compatible radiologic picture can be presumed to have PML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/7\">",
"     7",
"    </a>",
"    ]. As a result, PCR has now become an established way to ascertain the diagnosis of PML. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/7/44151?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\", section on 'Progressive multifocal leukoencephalopathy'",
"    </a>",
"    .) Nevertheless, HIV-positive patients with low CD4+ T cell counts who present with clinical and radiologic findings consistent with PML, should be considered as having \"possible PML\" even if JCV PCR is negative in the CSF, if other diagnoses have been ruled out, based on consensus terminology criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of using PCR for EBV DNA is less clear, as the sensitivity and specificity have varied widely depending upon whether the assay is performed in a research setting or a clinical laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14,48\">",
"     14,48",
"    </a>",
"    ]. Although a positive EBV DNA PCR in an immunosuppressed patient with findings consistent with PCNSL is supportive of the diagnosis, it does not exclude other causes of CNS disease. A conservative approach consists of confirming the diagnosis with a brain biopsy, taking into account the risks inherent with this procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCR has not been helpful for the detection of Toxoplasma gondii in CSF, with a sensitivity of only 50 percent, although specificity ranges from 96 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/7,14,42\">",
"     7,14,42",
"    </a>",
"    ]. In contrast, PCR has become an important tool for the diagnosis of CMV encephalitis, with a reported sensitivity exceeding 80 percent and a specificity of 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/7,49\">",
"     7,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Predictive value of clinical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators from Italy performed a decision analysis on 136 consecutive HIV patients presenting with focal CNS lesions in the pre-HAART era between 1991 and 1995 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14\">",
"     14",
"    </a>",
"    ]. Following three weeks of empiric therapy for TE, patients with progressive disease underwent a brain biopsy. In 66 patients, CSF PCR amplification for T. gondii, EBV, and JCV DNA was performed. The following results were calculated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The probability of TE was 0.87 in Toxoplasma seropositive patients with mass effect who were not on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX), but only 0.59 for those receiving prophylaxis.",
"     </li>",
"     <li>",
"      In Toxoplasma seropositive patients receiving TMP-SMX, the probability of PCNSL was 0.36.",
"     </li>",
"     <li>",
"      In Toxoplasma seronegative patients with mass effect, the probability of PCNSL was 0.74, which increased to 0.96 if EBV PCR was positive in the CSF.",
"     </li>",
"     <li>",
"      Among focal brain lesions without mass effect, the probability of PML was 0.81, which increased to 0.99 if JCV DNA was detected in the CSF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Empiric Toxoplasma therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial of empiric therapy for possible TE may be considered as an alternative to brain biopsy when the above tests have not clearly identified a specific cause in a patient who presents with focal CNS pathology but does not have manifestations of mass effect requiring early brain biopsy. Thus, clinical symptoms and signs, neuroimaging, CD4 cell count, serologies, PCR results, and use of concomitant medications, which could alter the diagnostic considerations, all need to be weighed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the patient have advanced immunosuppression? If not, then tumors such as glioblastoma or metastatic disease need to be excluded, as in HIV-seronegative patients. If the patient has severe immunosuppression, then TE, PCNSL, and PML are the leading diagnostic considerations.",
"     </li>",
"     <li>",
"      Does the patient have multiple lesions, which are radiologically consistent with TE or PCNSL? If serologic studies show that the patient is seropositive for Toxoplasma, then TE becomes more likely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14\">",
"       14",
"      </a>",
"      ]. However, as noted in the previous section, the likelihood of TE is much lower if the seropositive patient is taking TMP-SMX for prophylaxis for Pneumocystis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/3,14\">",
"       3,14",
"      </a>",
"      ]. The possibility of TE is also low (about 5 percent) if the patient is seronegative for Toxoplasma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/7\">",
"       7",
"      </a>",
"      ]. In these settings, a brain biopsy should be pursued rapidly to make a diagnosis.",
"     </li>",
"     <li>",
"      Does the patient have a large solitary lesion greater than 4 cm in diameter? If so, then PCNSL is most likely and tissue diagnosis is helpful. An empiric trial of treatment for TE is often employed if there is no immediate concern for herniation risk. An imaging study should be repeated in approximately one week with plans for early biopsy if no improvement is seen.",
"     </li>",
"     <li>",
"      Does the patient have asymmetric lesions without mass effect that primarily involve white matter? In this setting, PML is the leading diagnosis and CSF examination can help make a presumptive diagnosis if JC virus can be isolated. Empiric Toxoplasma therapy is",
"      <strong>",
"       not",
"      </strong>",
"      warranted in such patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The empiric regimen for possible TE is discussed separately. Empiric therapy is usually given for 10 to 14 days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is critical to closely monitor the patient's neurologic examination during a trial of empiric therapy. Clinical improvement is expected within one to two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/50\">",
"     50",
"    </a>",
"    ]. The diagnosis of TE is established if the patient clinically improves and there is a reduction in lesion size within two weeks. A brain biopsy should be considered in patients who do not have clinical and radiologic improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroid therapy should be considered in two settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When substantial mass effect can be demonstrated on imaging and the mental status is significantly depressed. Such patients are at risk for cerebral herniation.",
"     </li>",
"     <li>",
"      When the diagnosis of PCNSL has already been established, since steroids can cause false negative results on a subsequent brain biopsy in patients with lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common regimen is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    given intravenously as a 10 mg loading dose followed by 4 mg Q6h; the drug should be discontinued as soon as possible. This regimen will decrease brain swelling whether or not the mass is due to infection. As a result, a clear response to therapy is of no value in diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Brain biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic brain biopsy is the gold standard for the diagnosis of focal CNS lesions in AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/2,7\">",
"     2,7",
"    </a>",
"    ], since several studies have demonstrated the inadequacy of clinical acumen alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/2,51\">",
"     2,51",
"    </a>",
"    ]. However, biopsy may not be possible with lesions in certain locations.",
"   </p>",
"   <p>",
"    The overall reported complication rate has ranged from 0 to 3.1 percent mortality, 0.5 to 9 percent major morbidity, and 2 to 4 percent minor morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14,52-54\">",
"     14,52-54",
"    </a>",
"    ]. The outcomes are better in centers with technical expertise.",
"   </p>",
"   <p>",
"    A definitive diagnosis is reached in as many as 93 to 96 percent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14,53\">",
"     14,53",
"    </a>",
"    ]. This is important clinically, since the prognosis of HIVE and PML has improved dramatically with the advent of HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41128/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4660646\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most important factor in determining the differential diagnosis in an HIV-infected patient with suspected central nervous system (CNS) pathology is the degree of immunosuppression in the host. CNS mass lesions are most common in severely immunosuppressed patients with CD4 cell counts",
"      <span class=\"nowrap\">",
"       &lt;200/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The leading diagnostic considerations in a patient with advanced immunosuppression are Toxoplasma encephalitis, primary CNS lymphoma, progressive multifocal leukoencephalopathy, HIV encephalopathy, and CMV encephalitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The discovery of a CNS lesion is made by head CT or MRI. These examinations must be performed before and after injection of contrast material to determine whether a lesion enhances on neuroimaging. Enhancement usually signifies the presence of inflammation. An MRI is more sensitive than a head CT in determining if a lesion is truly solitary. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiologic appearance of CNS lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CNS mass lesions are characterized by the presence of swelling, edema, and mass effect on surrounding structures. The two leading diagnoses associated with mass effect in developed countries are Toxoplasma encephalitis and primary central system lymphoma. In the developing world, tuberculomas are a leading diagnostic consideration. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CNS lesions with mass effect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lesions without mass effect usually do not enhance after the injection of contrast material and are not associated with a risk of herniation. The vast majority of these lesions are due to progressive multifocal leukoencephalopathy or HIV-associated encephalopathy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'CNS lesions without mass effect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar puncture is contraindicated in patients with focal signs or with lesions producing mass effect, especially in the posterior fossa, due to the risk of transtentorial herniation. If the patient does not have any focality on examination and mass effect is not evident, then consideration should be given to cerebrospinal fluid (CSF) examination, although its utility is limited.",
"     </li>",
"     <li>",
"      CSF cytology can help in the diagnosis of lymphoma if it is positive, but this occurs in only 15 percent of cases with meningeal seeding. Polymerase chain reaction (PCR) analysis may assist in identifying the DNA of JC virus (the causative agent of PML), Epstein-Barr virus (associated with lymphoma), and Toxoplasma gondii. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'CSF examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A trial of empiric therapy for possible TE may be considered as an alternative to brain biopsy when in a patient who presents with focal CNS pathology but does not have manifestations of mass effect requiring early brain biopsy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Empiric Toxoplasma therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Corticosteroid therapy should be considered in the presence of mass effect since these patients are at increased risk of herniation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stereotactic brain biopsy is the gold standard for the diagnosis of focal CNS lesions in AIDS, since several studies have demonstrated the inadequacy of clinical acumen alone. However, biopsy may not be possible with lesions in certain locations. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Brain biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/1\">",
"      Stenzel W, Pels H, Staib P, et al. Concomitant manifestation of primary CNS lymphoma and Toxoplasma encephalitis in a patient with AIDS. J Neurol 2004; 251:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/2\">",
"      Gildenberg PL, Gathe JC Jr, Kim JH. Stereotactic biopsy of cerebral lesions in AIDS. Clin Infect Dis 2000; 30:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/3\">",
"      Ammassari A, Scoppettuolo G, Murri R, et al. Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/4\">",
"      Gray F, Chr&eacute;tien F, Vallat-Decouvelaere AV, Scaravilli F. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003; 62:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/5\">",
"      d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/6\">",
"      Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002; 16:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/7\">",
"      Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/8\">",
"      Whiteman ML, Post MJ, Berger JR, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993; 187:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/9\">",
"      Modi M, Mochan A, Modi G. Management of HIV-associated focal brain lesions in developing countries. QJM 2004; 97:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/10\">",
"      Miller RF, Hall-Craggs MA, Costa DC, et al. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS. Sex Transm Infect 1998; 74:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/11\">",
"      Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/12\">",
"      So YT, Beckstead JH, Davis RL. Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathological study. Ann Neurol 1986; 20:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/13\">",
"      Ciacci JD, Tellez C, VonRoenn J, Levy RM. Lymphoma of the central nervous system in AIDS. Semin Neurol 1999; 19:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/14\">",
"      Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997; 48:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/15\">",
"      Troncoso A, Fumagalli J, Shinzato R, et al. CNS cryptococcoma in an HIV-positive patient. J Int Assoc Physicians AIDS Care (Chic) 2002; 1:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/16\">",
"      Cohen WA. Intracranial bacterial infections in patients with AIDS. Neuroimaging Clin N Am 1997; 7:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/17\">",
"      Farrar DJ, Flanigan TP, Gordon NM, et al. Tuberculous brain abscess in a patient with HIV infection: case report and review. Am J Med 1997; 102:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/18\">",
"      Miszkiel KA, Hall-Craggs MA, Miller RF, et al. The spectrum of MRI findings in CNS cryptococcosis in AIDS. Clin Radiol 1996; 51:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/19\">",
"      Roeske LC, Kennedy PR. Images in clinical medicine. Syphilitic gummas in a patient with human immunodeficiency virus infection. N Engl J Med 1996; 335:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/20\">",
"      Manfredi R, Salfi N, Alampi G, et al. AIDS-related visceral aspergillosis: an underdiagnosed disease during life? Mycoses 1998; 41:453.",
"     </a>",
"    </li>",
"    <li>",
"     Tan, K, Roda, R, Ostrow, L, et al. PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/22\">",
"      Morgello S, Cho ES, Nielsen S, et al. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature. Hum Pathol 1987; 18:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/23\">",
"      Miller RF, Lucas SB, Hall-Craggs MA, et al. Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS. J Neurol Neurosurg Psychiatry 1997; 62:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/24\">",
"      Moulignier A, Mikol J, Gonzalez-Canali G, et al. AIDS-associated cytomegalovirus infection mimicking central nervous system tumors: a diagnostic challenge. Clin Infect Dis 1996; 22:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/25\">",
"      Borggreve F, Dierckx RA, Crols R, et al. Repeat thallium-201 SPECT in cerebral lymphoma. Funct Neurol 1993; 8:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/26\">",
"      Ruiz A, Ganz WI, Post MJ, et al. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. AJNR Am J Neuroradiol 1994; 15:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/27\">",
"      Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999; 17:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/28\">",
"      Skiest DJ, Erdman W, Chang WE, et al. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000; 40:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/29\">",
"      Kessler LS, Ruiz A, Donovan Post MJ, et al. Thallium-201 brain SPECT of lymphoma in AIDS patients: pitfalls and technique optimization. AJNR Am J Neuroradiol 1998; 19:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/30\">",
"      Ernst TM, Chang L, Witt MD, et al. Cerebral toxoplasmosis and lymphoma in AIDS: perfusion MR imaging experience in 13 patients. Radiology 1998; 208:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/31\">",
"      Chang L, Ernst T, Tornatore C, et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997; 48:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/32\">",
"      Simone IL, Federico F, Tortorella C, et al. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry 1998; 64:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/33\">",
"      O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997; 38:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/34\">",
"      Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS 1996; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/35\">",
"      Roberts TC, Storch GA. Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis. J Clin Microbiol 1997; 35:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/36\">",
"      Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, et al. Comprehensive investigation of the presence of JC virus in AIDS patients with and without progressive multifocal leukoencephalopathy. J Med Virol 1997; 52:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/37\">",
"      Gibson PE, Knowles WA, Hand JF, Brown DW. Detection of JC virus DNA in the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Med Virol 1993; 39:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/38\">",
"      Moret H, Guichard M, Matheron S, et al. Virological diagnosis of progressive multifocal leukoencephalopathy: detection of JC virus DNA in cerebrospinal fluid and brain tissue of AIDS patients. J Clin Microbiol 1993; 31:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/39\">",
"      Weber T, Turner RW, Frye S, et al. Progressive multifocal leukoencephalopathy diagnosed by amplification of JC virus-specific DNA from cerebrospinal fluid. AIDS 1994; 8:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/40\">",
"      Fong IW, Britton CB, Luinstra KE, et al. Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Clin Microbiol 1995; 33:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/41\">",
"      McGuire D, Barhite S, Hollander H, Miles M. JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy. Ann Neurol 1995; 37:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/42\">",
"      Cinque P, Vago L, Dahl H, et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 1996; 10:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/43\">",
"      Koralnik IJ, Boden D, Mai VX, et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/44\">",
"      Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005; 40:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/45\">",
"      Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/46\">",
"      Marzocchetti A, Di Giambenedetto S, Cingolani A, et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43:4175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/47\">",
"      Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003; 9 Suppl 1:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/48\">",
"      Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis 2004; 38:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/49\">",
"      Arribas JR, Clifford DB, Fichtenbaum CJ, et al. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis 1995; 172:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/50\">",
"      Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/51\">",
"      Hornef MW, Iten A, Maeder P, et al. Brain biopsy in patients with acquired immunodeficiency syndrome: diagnostic value, clinical performance, and survival time. Arch Intern Med 1999; 159:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/52\">",
"      Holloway RG, Mushlin AI. Intracranial mass lesions in acquired immunodeficiency syndrome: using decision analysis to determine the effectiveness of stereotactic brain biopsy. Neurology 1996; 46:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/53\">",
"      Levy RM, Russell E, Yungbluth M, et al. The efficacy of image-guided stereotactic brain biopsy in neurologically symptomatic acquired immunodeficiency syndrome patients. Neurosurgery 1992; 30:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/54\">",
"      Antinori A, Ammassari A, Luzzati R, et al. Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS &amp; Tumori. Neurology 2000; 54:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/55\">",
"      Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998; 12:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/56\">",
"      Filippi CG, Sze G, Farber SJ, et al. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 1998; 206:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41128/abstract/57\">",
"      Baqi M, Kucharczyk W, Walmsley SL. Regression of progressive multifocal encephalopathy with highly active antiretroviral therapy. AIDS 1997; 11:1526.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3718 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-A3347AB727-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41128=[""].join("\n");
var outline_f40_10_41128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4660646\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RADIOLOGIC APPEARANCE OF CNS LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CNS lesions with mass effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Toxoplasma encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CNS lesions without mass effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Progressive multifocal leukoencephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - HIV encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cytomegalovirus encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ancillary imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CSF examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Predictive value of clinical factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Empiric Toxoplasma therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Brain biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4660646\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3718|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/7/22655\" title=\"algorithm 1\">",
"      Management of HIV patients with CNS lesions algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3718|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/45/37588\" title=\"diagnostic image 1\">",
"      AIDS patient with PML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/9/27792\" title=\"diagnostic image 2\">",
"      Toxoplasma encephalitis MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/59/2992\" title=\"diagnostic image 3\">",
"      Primary CNS lymphoma MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3718|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/17/32016\" title=\"diagnostic image 4\">",
"      HIV encephalopathy MRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7623?source=related_link\">",
"      AIDS-related cytomegalovirus neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28232?source=related_link\">",
"      Clinical manifestations and diagnosis of cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12249?source=related_link\">",
"      Dementia and delirium in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_10_41129="Emergencies in pediatric cancer patients";
var content_f40_10_41129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergencies in pediatric cancer patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41129/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41129/contributors\">",
"     Dean A Lee, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41129/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41129/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41129/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/10/41129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26748618\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with cancer are at increased risk for life-threatening complications either due to their malignancy or its treatment. Although close monitoring of pediatric cancer patients allows pediatric oncologists to recognize and manage many potential complications before they become emergencies, some emergencies will develop acutely and require initial diagnosis and management by emergency room physicians or primary care providers. Early recognition, evaluation, and treatment of these potentially serious and at times life-threatening events are important to reduce morbidity and mortality in pediatric cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The more common emergencies seen in children with cancer will be reviewed here. Signs and symptoms that childhood cancer share with other pediatric illnesses at presentation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=see_link\">",
"     \"Clinical assessment of the child with suspected cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35398440\">",
"    <span class=\"h1\">",
"     INFECTION AND FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric cancer patients are at risk for serious infection because of their impaired immune response, particularly during periods of neutropenia. In these patients, fever is the most common and often the first manifestation of a life-threatening infection, such as septic shock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At initial diagnosis, pediatric cancer patients often present with fever due to an infection as a consequence of their underlying malignancies that impair their immunologic response. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical assessment of the child with suspected cancer\", section on 'Fever'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Later during treatment, pediatric cancer patients may also present with fever due to an infection as a consequence of chemotherapy-induced neutropenia. The evaluation, etiology, and treatment of the pediatric child with fever and chemotherapy-induced neutropenia are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15898?source=see_link\">",
"       \"Fever in children with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Finally, pediatric cancer patients may present at diagnosis or relapse with fever that is a consequence of cytokine release from the malignancy itself, as is common in leukemia, lymphoma, and neuroblastoma patients. The possibility that fever may not be caused by infection should never delay empiric therapy of new-onset fever. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical assessment of the child with suspected cancer\", section on 'Fever'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26748664\">",
"    <span class=\"h1\">",
"     CARDIOPULMONARY EMERGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pediatric cancer patients, cardiopulmonary emergencies generally present with respiratory distress, chest pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of venous congestion. Causes of these emergencies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pleural effusions",
"     </li>",
"     <li>",
"      Pericardial effusions, which may result in cardiac tamponade",
"     </li>",
"     <li>",
"      Hemoptysis",
"     </li>",
"     <li>",
"      Superior vena cava (SVC) and superior mediastinal (SM) syndromes",
"     </li>",
"     <li>",
"      Pneumonia (See",
"      <a class=\"local\" href=\"#H35398440\">",
"       'Infection and fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiotoxicity from chemotherapy (eg, adriamycin) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In rare cases, obstruction from a cardiac neoplasm, such as atrial myxomas (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link&amp;anchor=H14#H14\">",
"       \"Cardiac tumors\", section on 'Myxomas'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106214698\">",
"    <span class=\"h2\">",
"     Pleural and pericardial effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural and pericardial effusions are caused by the movement of fluid into the potential spaces of either the pleura or pericardium. The fluid may either be exudative caused by the primary malignancy, inflammation, or infection, or transudative due to imbalance of the hydrostatic and osmotic forces across the pleural membrane or pericardial sac.",
"   </p>",
"   <p>",
"    Symptoms include dyspnea, chest pain, and cough. Large pleural effusions may result in respiratory distress, whereas a large pericardial effusion may cause cardiac tamponade.",
"   </p>",
"   <p>",
"    Management generally is directed to removal of fluid. Fluid may reaccumulate over a period of hours to days in patients with advanced malignancy, in whom the underlying tumor is the cause of the effusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106214708\">",
"    <span class=\"h3\">",
"     Cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac tamponade is the most serious consequence of a pericardial effusion and occurs when fluid accumulation compresses the heart chambers resulting in a reduction in venous return and a subsequent decrease in cardiac output. The physical findings, diagnosis, and management of cardiac tamponade are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106215233\">",
"    <span class=\"h2\">",
"     Hemoptysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, tumors are rare causes of pulmonary hemorrhage, but rather infection, particularly aspergillosis, is the typical cause of hemoptysis in children with cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37896?source=see_link&amp;anchor=H6#H6\">",
"     \"Hemoptysis in children\", section on 'Pulmonary parenchymal diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26748672\">",
"    <span class=\"h2\">",
"     SVC and SM syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superior vena cava syndrome (SVCS) and superior mediastinal syndrome (SMS) represent overlapping disorders that may occur as rare complications of chest masses in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SVCS refers to the signs and symptoms of upper body venous congestion resulting from obstruction of adequate venous return through the superior vena cava (SVC). It may occur from extrinsic compression of the SVC by a mass or intrinsic obstruction secondary to thrombosis. Internal obstruction occurs most commonly as a complication of long-term central venous catheters, but may also occur spontaneously in some malignancies that are associated with thrombotic states.",
"     </li>",
"     <li>",
"      SMS refers to the clinical signs and symptoms that occur as a result of the compression of structures that pass through the potential space of the superior mediastinum, and may include both venous (SVCS) and airway compression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26748715\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mediastinal malignancy is the underlying cause of SVCS in 90 percent of pediatric cases with two-thirds of these being acute lymphoblastic leukemia (ALL, particularly T cell phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/2\">",
"     2",
"    </a>",
"    ]) and lymphoma, followed by sarcomas, neuroblastoma and germ cell tumors (GCTs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/3\">",
"     3",
"    </a>",
"    ]. Although GCTs occur less frequently, up to 20 percent of GCTs are associated with SVCS. Neurogenic tumors such as neuroblastoma most frequently arise in the posterior mediastinum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/4\">",
"     4",
"    </a>",
"    ] and are less likely to compress the SVC or the airway. Non-malignant masses (ie, teratomas, granulomas, or cysts) are also common causes of a chest mass in children and may cause SVCS.",
"   </p>",
"   <p>",
"    In a case series of 24 children with SVCS from St Jude Children&rsquo;s Hospital, the malignancies associated with SVCS included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-Hodgkin&rsquo;s disease (n = 8)",
"     </li>",
"     <li>",
"      Acute lymphoblastic leukemia with mediastinal mass (n = 6)",
"     </li>",
"     <li>",
"      Sarcomas (n = 3)",
"     </li>",
"     <li>",
"      Neuroblastoma (n = 3)",
"     </li>",
"     <li>",
"      Hodgkin&rsquo;s disease (n = 2)",
"     </li>",
"     <li>",
"      Germ cell tumors (n = 2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic airway compromise is more common in children with mediastinal masses than in adults because the airway is smaller and the cartilaginous rings of the upper airway are less developed resulting in a more compliant and compressible upper airway (ie, trachea and mainstem bronchi). Venous congestion in the upper body manifests as surface venular dilation, and edema of the arms, face, and neck. Central nervous system symptoms may also occur, from simple headache to mental status changes, probably secondary to increased intracranial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/6\">",
"     6",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    From the above case series, the most common symptoms and findings including their frequency were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Cough/dyspnea",
"      </span>",
"      (68 percent)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Dysphagia/orthopnea",
"      </span>",
"      (63 percent)",
"     </li>",
"     <li>",
"      Pleural effusions (50 percent)",
"     </li>",
"     <li>",
"      Wheezing (31 percent)",
"     </li>",
"     <li>",
"      Hoarse voice (19 percent)",
"     </li>",
"     <li>",
"      Pericardial effusion (19 percent)",
"     </li>",
"     <li>",
"      Facial edema (12 percent)",
"     </li>",
"     <li>",
"      Chest pain (6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26748782\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SVCS is generally made by chest radiography (",
"    <a class=\"graphic graphic_algorithm graphicRef78852 \" href=\"mobipreview.htm?7/53/8030\">",
"     algorithm 1",
"    </a>",
"    ). Plain radiographs of the chest are effective in establishing the presence of 97 percent of mediastinal masses, and should be obtained in any child who presents with respiratory compromise or venous congestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases in which the chest radiograph is not diagnostic, other imaging modalities may be useful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the setting of suspected airway compromise, computed tomography (CT) is the easiest and safest modality.",
"     </li>",
"     <li>",
"      In the setting of isolated SVCS, magnetic resonance (MR) angiography may provide better evaluation of venous flow.",
"     </li>",
"     <li>",
"      Echocardiography should be performed when cardiac compromise is suspected by physical examination.",
"     </li>",
"     <li>",
"      Ultrasound with Doppler flow imaging evaluates the degree of obstruction to venous flow, and in many cases can identify the presence of a mass or thrombus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When feasible, imaging procedures should be performed in a position that is comfortable for the patient (prone, side-lying, or recumbent, which reduce the pressure of the mass on the airways) without sedation and with as little agitation as possible. Negative intrathoracic pressures from spontaneous respirations reduce pressure on low-pressure vessels and airways, and this may be lost during sedation or with positive-pressure ventilation during anesthesia.",
"   </p>",
"   <p>",
"    Computed tomography (CT) is preferred to magnetic resonance imaging (MRI) because it can be done more quickly and is more likely to accommodate alternate positions. In addition, it is better able to depict margins, calcifications, and lung nodules than MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26748829\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate supportive care measures include supplemental oxygen administration, elevation of the head, proper positioning of the patient to minimize the obstruction, maintenance of a calm and quiet environment, moderate diuresis, and admission to the intensive care unit once initial stabilization is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19905530\">",
"    <span class=\"h4\">",
"     Mediastinal tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of a malignancy causing compression of vital structures requires a clear diagnosis of the underlying tumor. However, medical intervention is often indicated before a diagnosis can be made. In this circumstance, a clinical decision must balance the need to preserve tissue architecture for an accurate diagnosis, against the need to intervene quickly to relieve a serious, and perhaps life-threatening, condition (",
"    <a class=\"graphic graphic_algorithm graphicRef78852 \" href=\"mobipreview.htm?7/53/8030\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are no established standards for empiric therapy of symptomatic chest masses. However, intervention may make future biopsies difficult to perform or not interpretable for diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conformal radiotherapy at doses up to 200cGy given once or twice daily is commonly used to reduce tumor size resulting in decompression of the vital organs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1,10,11\">",
"       1,10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      While administration of corticosteroids alone may be effective in rapidly reducing mediastinal masses due to lymphoid malignancies, its effect on sarcomas is less predictable when used as monotherapy. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      However, the addition of intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      <span class=\"nowrap\">",
"       (40mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day given in three divided doses) to radiotherapy may be synergistic in children with leukemia or lymphoma and may help to prevent exacerbation of the mass effect secondary to radiation-induced edema in other malignancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Procuring tissue for pathologic diagnosis should be done in the least invasive manner and without sedation if possible, as mentioned above for imaging procedures. Published reports of the adverse effects of anaesthesia in patients with mediastinal masses suggest that children are much more likely to suffer major morbidity or mortality than are adults, and clear preoperative planning by the entire surgical team is essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local analgesia for biopsy of a superficial lymph node is preferred, and should be performed at a pediatric cancer institute where maximum utilization of the tissue for diagnosis by a pediatric pathologist can be ensured.",
"     </li>",
"     <li>",
"      If local analgesia is not sufficient, the risk of sedation must be weighed against the risk of empiric treatment based on patient age, tumor location, and associated findings. In this setting, sedation should be managed by an experienced pediatric anesthesiologist. Spontaneous respirations should be maintained as much as possible. Although evaluation by the cardiothoracic service had been recommended prior to administrations of sedation, in order to be prepared for the possible use of cardiopulmonary bypass in the event of complete airway obstruction, few accounts of successful emergency bypass have been reported, and some have argued that this practice is no longer appropriate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A complete blood count including platelet count and differential should be obtained prior to the procedure and may be diagnostic in the case of leukemia.",
"     </li>",
"     <li>",
"      In the presence of a pleural or pericardial effusion, paracentesis may be therapeutic and diagnostic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19905537\">",
"    <span class=\"h4\">",
"     Venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation is indicated for SVCS secondary to venous thrombosis. Therapeutic doses of low molecular weight",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) are preferred, but unfractionated heparin may also be used. The use of thrombolytics and intravascular stents has not been established in children, although some case reports are described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and several studies are available in the adult literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. If the clot is in association with a central venous catheter, the catheter should be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26748954\">",
"    <span class=\"h1\">",
"     ABDOMINAL EMERGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal emergencies may occur in pediatric cancer patients as complications of either primary disease or cancer treatment. These emergencies include intestinal obstruction, perforation, hemorrhage, typhlitis (neutropenic enterocolitis), and acute pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26748961\">",
"    <span class=\"h2\">",
"     Acute bowel obstruction/intussusception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bowel obstruction may be secondary to external compression, constriction, or internal obstruction. Constriction from adhesions or strictures is more common as a post-surgical complication. Internal obstruction from intussusception is often related to intramural lymphoid hyperplasia in acute lymphoblastic leukemia or lymphoma, and particularly in Burkitt&rsquo;s lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749009\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of bowel obstruction is based on a combination of clinical and radiographic features. It needs to be distinguished from nonobstructive intestinal motility disorders such as paralytic ileus, which is commonly associated with narcotic agents and vinca alkaloids (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Symptoms of bloody stools, colicky abdominal pain, intractable emesis, and palpable mass should prompt an evaluation for acute bowel obstruction. In proximal obstruction, nausea and vomiting can be relatively severe compared to distal obstruction.",
"   </p>",
"   <p>",
"    Imaging is helpful in establishing the diagnosis of small bowel obstruction. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enemas, commonly used for both diagnosis and treatment of intussusception in the otherwise healthy child, should be avoided in the child with neutropenia or recently treated with radiation or chemotherapy because of the risk of infection or rupture of thinned gut mucosa. The manifestations and diagnosis of small bowel obstruction and intussusception, including a discussion on imaging modalities, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749016\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with pediatric surgery should be made early. Although surgery after high-dose chemotherapy should be approached with caution because of risks associated with neutropenia and poor wound healing, surgical intervention is indicated for complete bowel obstruction because a delay in correcting the obstruction may result in further bowel injury including necrosis and the possible need for resection and ileostomy.",
"   </p>",
"   <p>",
"    Conservative management may be indicated in the setting of partial small bowel obstruction at the discretion of the surgeon. Keeping the patient NPO with nasogastric suction may provide sufficient decompression to resolve the obstruction. However, partial obstruction may rapidly become complete obstruction if untreated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749023\">",
"    <span class=\"h2\">",
"     Perforation/hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel wall perforation and acute abdominal hemorrhage have overlapping etiologies and may occur simultaneously. They are most often caused by erosion due to tumor infiltration and necrosis in a rapidly growing tumor through the bowel wall or vessels, respectively. In the pediatric patient, this is most common with rapidly growing intestinal lymphomas such as Burkitt's lymphoma.",
"   </p>",
"   <p>",
"    Mucosal erosion may also occur following high-dose chemotherapy with direct damage to the mucosal epithelium, or from sustained use of ulcer-promoting medications such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . Bacterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungal invasion with bowel wall necrosis are hallmarks of typhlitis. (See",
"    <a class=\"local\" href=\"#H26749064\">",
"     'Typhlitis (Neutropenic enterocolitis)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bleeding as a complication of erosion may be acute or subacute and may be further exacerbated by thrombocytopenia or coagulation abnormalities in the cancer patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749037\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The suspicion of perforation or hemorrhage should be made clinically on the basis of abdominal symptoms and examination (ie, abdominal tenderness and distension, decreased bowel sounds, emesis, hematemesis or melena), changing vital signs (ie, fever, hypotension, and tachycardia), and predisposing patient factors (ie, prolonged corticosteroid therapy, Burkitt&rsquo;s lymphoma, abdominal irradiation, or recent chemotherapy).",
"   </p>",
"   <p>",
"    Plain abdominal radiographs may demonstrate free air in the upright position under the diaphragm, or in the supine position along the falciform ligament (&ldquo;foot-ball sign&rdquo;). Air-fluid levels suggestive of ileus may be present. Abdominal ultrasound may be helpful in delineating free fluid in the absence of free air, as will non-contrast CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749044\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt involvement of a pediatric surgeon is essential. If either perforation or hemorrhage is suspected, the clinician should direct initial therapy as if both diagnoses are present until proven otherwise. Frequent vital signs, prompt administration of broad-spectrum antibiotics to cover usual gut flora (including anaerobic organisms), serial CBCs to address the rate of blood loss and the need for transfusion of red cells and platelets, and adequate volume expansion should be performed as needed. Coagulation studies will help address the need for fresh frozen plasma in stabilizing the patient or in preparation for surgery. Packed red cells should be cross-matched and available even if not needed immediately. Administration of intravenous histamine-2 (H2) blockers can prevent further erosion and clot dissolution in gastric erosions. Management of GI bleeding or perforation in the neutropenic patient should be tempered by the consideration of typhlitis (See",
"    <a class=\"local\" href=\"#H26749064\">",
"     'Typhlitis (Neutropenic enterocolitis)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While some cases may be managed non-operatively, definitive therapy for bowel perforation and hemorrhage is often surgical repair of the affected bowel and vessels with copious irrigation and broad-spectrum postoperative antibiotics until the patient has recovered bowel function, is hemodynamically stable, and has defervesced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749064\">",
"    <span class=\"h2\">",
"     Typhlitis (Neutropenic enterocolitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhlitis (from the Greek word \"typhlon,\" or cecum) is synonymous with \"neutropenic enterocolitis\" and is defined by bacterial invasion into cecal mucosa in the neutropenic patient. It is caused by the unchecked bacterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungal invasion of the bowel wall during periods of prolonged neutropenia. Typhlitis has been observed in the setting of induction therapy in patients with acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia, or following aggressive chemotherapy in patients with solid tumors. The diagnosis and management of typhlitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27125?source=see_link\">",
"     \"Typhlitis (neutropenic enterocolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197248640\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-associated pancreatitis due to L-asparaginase is seen in 2 percent of children with acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/21\">",
"     21",
"    </a>",
"    ]. Pancreatitis should be considered in any child with vomiting and abdominal pain who has received L-asparaginase.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of pancreatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749221\">",
"    <span class=\"h1\">",
"     UROLOGIC/RENAL EMERGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urologic and renal emergencies may be secondary to mass effects of tumor, rapid tumor lysis, or due to the effects of treatment. As an example, septic shock is the most common cause of acute renal injury in pediatric cancer patients receiving chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35398440\">",
"     'Infection and fever'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749253\">",
"    <span class=\"h2\">",
"     Obstructive uropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction of the urinary tract may be caused by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extrinsic compression by abdominal, retroperitoneal, or pelvic tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ureters &ndash; Wilms tumor or germ cell tumors",
"     </li>",
"     <li>",
"      Bladder &ndash; Pelvic sarcoma",
"     </li>",
"     <li>",
"      Urethra &ndash; Prostatic rhabdomyosarcoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrinsic obstruction by bladder rhabdomyosarcoma, nephrolithiasis, nephrocalcinosis, or clots at the bladder outlet due to chemotherapy-related hemorrhagic cystitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=see_link\">",
"       \"Cystitis in patients with cancer\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H26749330\">",
"       'Chemotherapy-related complications'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complete or prolonged partial urinary tract obstruction can lead to tubular atrophy and, eventually, irreversible renal injury. Obstructive uropathy needs to be distinguished from urinary retention that may be due to chemotherapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    ), narcotic agents, and intraspinal tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749292\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of obstructive uropathy should be considered in patients with decreased urine output,",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    pain or discomfort,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increase in serum creatinine. In some patients, hypertension may also be manifested. The diagnosis is made by imaging studies that demonstrate urinary obstruction.",
"   </p>",
"   <p>",
"    Renal ultrasonography is the preferred imaging modality, as it avoids radiation exposure and the potential complications of radiocontrast media. If the diagnosis remains inconclusive and the patient has adequate renal function (normal creatinine), CT with contrast may be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749311\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of obstructive uropathy is made, decompression and drainage of the urinary tract should be performed in patients with complete or prolonged partial obstruction. In some cases, consultation with a pediatric urologist may be required because of need for either ureteral stenting or nephrostomy tubes to decompress the urinary tract. Early recovery of urinary tract patency is essential for prompt resolution of renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24276?source=see_link\">",
"     \"Recovery of renal function after relief of urinary tract obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After decompression of the urinary tract, management is directed towards treating the underlying cause of the obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749330\">",
"    <span class=\"h2\">",
"     Chemotherapy-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapeutic agents cause several distinct immediate and delayed renal and urologic complications. The most common complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrocalcinosis and urate nephropathy due to tumor lysis syndrome or intratubular crystal formation can result in bilateral renal obstruction. The diagnosis should be considered for renal failure that occurs during induction chemotherapy and is supported by visualization of urate or calcium-phosphate crystals in a spun urine sample. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=see_link&amp;anchor=H2#H2\">",
"       \"Uric acid renal diseases\", section on 'Acute uric acid nephropathy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H26749851\">",
"       'Tumor lysis syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hypertension may be due to increased renin or aldosterone production due to renal arterial compression (eg, external compression by Wilms tumor) or hormonal-secreting tumors (eg, neuroblastoma), increased intracranial pressure from central nervous system tumors or their treatment, drug toxicity (eg, corticosteroids), or pain. The treatment of hypertension is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link\">",
"       \"Treatment of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct renal toxicity from chemotherapeutic agents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemorrhagic cystitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=see_link\">",
"       \"Cystitis in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749441\">",
"    <span class=\"h1\">",
"     NEUROLOGIC EMERGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic emergencies in pediatric cancer patients may occur as a result of the underlying tumor (eg, brain tumors that cause seizures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased intracranial pressure, and spinal cord tumors that may compress the spinal cord), tumor-associated abnormalities (eg, leukostasis), hematologic derangements leading to stroke (eg, thrombocytopenia), central nervous system infections from immunocompromise, or treatment-associated toxicities (eg, syndrome of inappropriate antidiuretic hormone secretion [SIADH] due to chemotherapeutic agents). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link\">",
"     \"Neurologic complications of platinum-based chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=see_link\">",
"     \"Complications of spinal cord irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749448\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric oncology patients are at risk for developing seizures as part of their primary disease or therapy. Seizures are most commonly due to focal cortical irritation from the underlying malignancy or direct toxicity of therapy (eg, intrathecal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37655?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or intracranial irradiation), or",
"    <span class=\"nowrap\">",
"     toxic/metabolic",
"    </span>",
"    effects of therapy (eg, hyponatremia in patients with SIADH) (",
"    <a class=\"graphic graphic_table graphicRef65165 \" href=\"mobipreview.htm?2/15/2300\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19904855\">",
"     'SIADH'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749475\">",
"    <span class=\"h3\">",
"     Diagnosis and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis at the initial event should be made by clinical appearance or description of the seizure event. A history should be obtained and includes family history, list of medications including chemotherapy and radiation therapy, and history of previous seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent evaluation for the etiology of the seizure should proceed as soon as the patient is stable and includes the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial laboratory evaluation should look for evidence of electrolyte abnormalities (including serum sodium, glucose, calcium, and magnesium) and potential for coagulopathy leading to an increased risk of intracranial bleeding (ie, activated partial thromboplastin time [aPTT], prothrombin time [PT], and complete blood count [CBC]).",
"     </li>",
"     <li>",
"      Neuroimaging (eg, computed tomography) should be obtained to evaluate for potential intracranial hemorrhage or thrombosis.",
"     </li>",
"     <li>",
"      If increased intracranial pressure is not apparent, cerebral spinal fluid should be obtained for cytology, protein, glucose, and infectious studies as clinically indicated (cultures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PCR for bacteria, viruses, and fungus).",
"     </li>",
"     <li>",
"      Electroencephalogram (EEG) should be obtained to evaluate for the presence of an ongoing seizure focus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749482\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures in the oncology patient are generally self-limited. Initial treatment should be directed at supporting vital functions (eg, airway, breathing, and circulation), and stopping prolonged seizure with short-acting benzodiazepines. Evaluation by a pediatric neurologist is indicated, and EEG may help direct the need for continued seizure prophylaxis. Initial anticonvulsant administration during the evaluation for the cause of the seizure is appropriate. Prophylaxis may be discontinued for those without evidence of a seizure focus on EEG and normal neuroimaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749501\">",
"    <span class=\"h2\">",
"     Altered mental status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered mental status is a spectrum of impaired consciousness states between complete unresponsiveness and full arousal, which include coma, lethargy (stupor), and delirium. There are many causes of altered mental status that occur in the pediatric patient with cancer (",
"    <a class=\"graphic graphic_table graphicRef76983 \" href=\"mobipreview.htm?37/46/38636\">",
"     table 2",
"    </a>",
"    ). Because of the potential morbidity or mortality of unrecognized progression of some of these etiologies, early recognition and a comprehensive evaluation is necessary as the primary intervention is to treat the underlying cause of AMS.",
"   </p>",
"   <p>",
"    The emergent evaluation and management of stupor and coma in children are summarized in the linked table (",
"    <a class=\"graphic graphic_table graphicRef62416 \" href=\"mobipreview.htm?4/22/4461\">",
"     table 3",
"    </a>",
"    ) and are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28136?source=see_link\">",
"     \"Evaluation of stupor and coma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19544?source=see_link\">",
"     \"Treatment and prognosis of coma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the above general approach, the following specific issues (and their management) are unique or more common in children with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/33/11800?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      encephalopathy:",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/61/20438?source=see_link\">",
"       Methylene blue",
"      </a>",
"     </li>",
"     <li>",
"      IL-2 toxicity: Corticosteroids",
"     </li>",
"     <li>",
"      Acute",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      toxicity: Carboxypeptidase (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"       \"Therapeutic use and toxicity of high-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Somnolence syndrome associated with cranial irradiation: Corticosteroids and stimulants may be helpful",
"     </li>",
"     <li>",
"      Delayed-onset",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      and radiation-induced toxicities are often reversible, and require only supportive care.",
"     </li>",
"     <li>",
"      Central nervous system lesion (mass or cerebrovascular accident): Request urgent neurology and neurosurgery support as indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749549\">",
"    <span class=\"h2\">",
"     Spinal cord compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression of the spinal cord may present with a prolonged history of complaints that are not focal neurological signs (eg, pain, constipation), but represents a true medical emergency because early diagnosis and intervention are critical to preserving and restoring neurologic function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injury to spinal cord neurons occurs by tumor compression and associated vasogenic edema of the cord within the rigid space of the spinal canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/22\">",
"     22",
"    </a>",
"    ]. Spinal cord compression may occur as a presenting symptom of a new malignancy, progression of a known malignancy, or edema associated with treatment. Primary or metastatic sarcomas account for a majority of pediatric oncologic cases of spinal cord compression, 50 percent of which are caused by neuroblastoma and Ewing&rsquo;s sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749630\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because 80 percent of children with spinal cord compression have a history of radicular back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ], children with cancer and back pain should be considered to have spinal cord compression until proven otherwise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/23\">",
"     23",
"    </a>",
"    ]. Other symptoms may include progressive weakness, sensory abnormalities, paresis, loss of",
"    <span class=\"nowrap\">",
"     bowel/bladder",
"    </span>",
"    function, and gait abnormalities. In the young child, constipation or refusal to ambulate may be the only symptoms.",
"   </p>",
"   <p>",
"    A thorough neurological examination should be performed to identify any neurologic impairment.",
"   </p>",
"   <p>",
"    An emergent MRI of the spine, with and without enhancement, should be obtained for any patient with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical findings suggestive of spinal cord compression. Plain films, bone scans, CT, and lumbar myelography are generally not adequate and delay obtaining the appropriate studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749661\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early consultation with a pediatric neurosurgeon, radiation oncologist, and neurologist should be obtained. High-dose corticosteroids (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered intravenously [IV]) should be given as soon as the diagnosis is considered, followed by lower doses (0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every six hours) when the diagnosis is established.",
"   </p>",
"   <p>",
"    Although clear guidelines have not been established, bulk reduction of the tumor mass, and thus cord decompression, should be sought immediately by surgical decompression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laminectomy, chemotherapy, or irradiation. Caution must be given to keep potential therapy-induced edema from causing further compression of the cord. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical decompression offers the most immediate relief, but laminectomy is associated with increased morbidity including growth complications (eg, scoliosis) in young children. Surgery is clearly indicated if there is progression of disease despite radiotherapy or chemotherapy, or for an unknown primary malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Either radiotherapy or chemotherapy may be considered for lesions less amenable to surgery (eg, disseminated or circumferential dural lesions) or in cases in which rapid progression is not apparent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"       1",
"      </a>",
"      ]. Radiotherapy may be indicated for tumors of known high radiosensitivity, and is given in doses of 180 to 400 cGy daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749704\">",
"    <span class=\"h2\">",
"     Leukostasis and hyperleukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukostasis is a pathologic condition in which white blood cell plugs develop in the microvasculature. It occurs in patients with leukemia because blast formation results in hyperleukocytosis, defined as a peripheral white blood cell count greater than 50,000 or 100,000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    &nbsp;",
"   </p>",
"   <p>",
"    Although pathologic evidence of leukostasis can be found in most organs in patients with hyperleukocytosis, the main clinical symptoms of leukostasis and causes of early death are related to involvement of the central nervous system (approximately 40 percent) and lungs (approximately 30 percent).",
"   </p>",
"   <p>",
"    Leukostasis (symptomatic hyperleukocytosis) constitutes a medical emergency, and efforts should be made to rapidly stabilize the patient and lower the white blood cell count. In most cases, rapid cytoreduction can be achieved with induction chemotherapy, which should be administered in conjunction with prophylaxis for tumor lysis syndrome.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and management of leukostasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=see_link\">",
"     \"Hyperleukocytosis and leukostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749843\">",
"    <span class=\"h1\">",
"     METABOLIC EMERGENCIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26749851\">",
"    <span class=\"h2\">",
"     Tumor lysis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor lysis syndrome is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. In children with cancer, it occurs most often after the initiation of cytotoxic therapy for ALL and high-grade lymphoma. The best management of tumor lysis syndrome is prevention, which consists of aggressive intravenous hydration, and the administration of hypouricemic agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/5/23636?source=see_link\">",
"     rasburicase",
"    </a>",
"    (recombinant human urate oxidase).",
"   </p>",
"   <p>",
"    The clinical manifestations, risk factors and stratification, prevention and management of tumor lysis syndrome are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26750049\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is defined as a serum calcium level greater than 12",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Calcium levels above this concentration can affect multiple organ systems, and levels above 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    can be fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/1\">",
"     1",
"    </a>",
"    ]. In children with cancer, hypercalcemia is usually due to increased bone resorption with release of calcium by bony metastasis of solid tumors or leukemic marrow infiltration. Increased bone resorption or renal conservation may also be caused by an increase in hormonal factors including parathyroid-related hormone (PTHrP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/25\">",
"     25",
"    </a>",
"    ] or calcitriol (particularly in lymphoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/26\">",
"     26",
"    </a>",
"    ]. The pathophysiology and etiology of hypercalcemia is described in further detail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26750122\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caution should be used in treating hypercalcemia during the initial treatment of malignancy, as subsequent tumor lysis is associated with hypocalcemia. The management of hypercalcemia includes fluid hydration with normal saline at a rate of 2000 to",
"    <span class=\"nowrap\">",
"     2400cc/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day, often in association with the administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    at 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    which increases renal excretion of calcium. If adequate, this approach is preferred because it is also helpful in the treatment of hyperphosphatemia and hyperuricemia of tumor lysis syndrome. Urine alkalinization should be avoided in the presence of high calcium and phosphorus levels (Ca x Ph &gt;70) because of increased potential for precipitation leading to nephrocalcinosis.",
"   </p>",
"   <p>",
"    In patients with serum calcium levels greater than 14",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/55/15220?source=see_link\">",
"     calcitonin",
"    </a>",
"    is used in the immediate short-term management and the use of bisphosphonates (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39781?source=see_link\">",
"     pamidronate",
"    </a>",
"    ) in longer-term control of hypercalcemia. Several successful case reports in children have been described, with the administration of pamidronate, a bisphosphonate, with doses ranging from 0.25 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (or 60",
"    <span class=\"nowrap\">",
"     mg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    ) given as a single intravenous dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. There is some evidence that the use of bisphosphonates may also prevent bone loss secondary to glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41129/abstract/31\">",
"     31",
"    </a>",
"    ], an additional problem in the treatment of leukemia.",
"   </p>",
"   <p>",
"    The treatment of hypercalcemia is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19904855\">",
"    <span class=\"h2\">",
"     SIADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of inappropriate secretion of antidiuretic hormone&nbsp;(SIADH) is a disorder in which water excretion is partially impaired resulting in hyponatremia, because of the inability to suppress the secretion of ADH. In pediatric cancer patients, hyponatremia due to SIADH is associated with some chemotherapeutic agents (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/33/11800?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/8/34949?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/41/43670?source=see_link\">",
"     melphalan",
"    </a>",
"    ), direct CNS injury either due to surgery or cranial irradiation, or, although rare in children, ADH-secreting tumors (eg, lymphoma). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severity of symptoms is dependent on the degree of hyponatremia. Nausea and malaise are the earliest findings, and may be seen when the plasma sodium concentration falls below 125 to 130",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    This may be followed by headache, lethargy, and obtundation and eventually seizures, coma, and respiratory arrest if the plasma sodium concentration falls below 120",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=see_link&amp;anchor=H3#H3\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Clinical manifestations of acute hyponatremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H357921784\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with cancer are at increased risk for life-threatening complications either due to their malignancy or its treatment. Although close monitoring of pediatric cancer patients allows pediatric oncologists to recognize and manage many potential complications before they become emergencies, many emergencies will develop acutely and require initial diagnosis and management by emergency room physicians or primary care providers. Early recognition, evaluation, and treatment of these potentially life-threatening events are important to reduce morbidity and mortality in pediatric cancer patients.",
"   </p>",
"   <p>",
"    The more common emergencies in pediatric cancer patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serious infection is a consequence of an impaired immune system, particularly during periods of neutropenia. Fever is the most common and often first manifestation of a life-threatening infection, such as septic shock. (See",
"      <a class=\"local\" href=\"#H35398440\">",
"       'Infection and fever'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"       \"Management of malignant pleural effusions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiopulmonary emergencies often present with respiratory distress, chest pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of venous congestions. They include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pleural and pericardial effusions. In some cases, cardiac tamponade may occur with larger accumulation of pericardial fluid that compresses the heart chambers resulting in reduced venous return and cardiac output. (See",
"      <a class=\"local\" href=\"#H106214698\">",
"       'Pleural and pericardial effusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemoptysis, which is generally caused by infection (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37896?source=see_link&amp;anchor=H6#H6\">",
"       \"Hemoptysis in children\", section on 'Pulmonary parenchymal diseases'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Superior vena cava (SVC) syndrome manifested as upper body venous congestion resulting from obstruction of SVC return by either venous thrombosis or external compression from mediastinal masses. Superior mediastinal syndrome is an overlapping disorder, in which mediastinal structures include both the airway and large vessels are obstructed by external compression by a mediastinal mass. (See",
"      <a class=\"local\" href=\"#H26748672\">",
"       'SVC and SM syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal emergencies include intestinal obstruction, perforation, hemorrhage, acute pancreatitis, and typhlitis (neutropenic enterocolitis). Typhlitis is caused by the unchecked bacterial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fungal invasion of the bowel wall during periods of prolonged neutropenia. (See",
"      <a class=\"local\" href=\"#H26748954\">",
"       'Abdominal emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urological and renal emergencies include obstructive uropathy, hemorrhagic cystitis, acute renal injury including renal failure, and hypertension. (See",
"      <a class=\"local\" href=\"#H26749221\">",
"       'Urologic/renal emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic emergencies may occur as a result of an underlying central nervous system tumor (eg, brain tumors that cause seizures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased intracranial pressure, and spinal cord tumors that may compress the spinal cord), tumor-associated abnormalities (eg, leukostasis or strokes due to thrombocytopenia), or due to treatment-associated toxicities (eg, central nervous system infections, or syndrome of inappropriate antidiuretic hormone secretion [SIADH] due to chemotherapeutic agents). Symptoms include seizures, mental status changes (eg, coma), spinal cord compression, and stroke. (See",
"      <a class=\"local\" href=\"#H26749441\">",
"       'Neurologic emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic emergencies include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tumor lysis syndrome caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercalcemia (See",
"      <a class=\"local\" href=\"#H26750049\">",
"       'Hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe hyponatremia (plasma sodium concentration below 120",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      caused by SIADH (See",
"      <a class=\"local\" href=\"#H19904855\">",
"       'SIADH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fisher MJ, Rheingold, SR. Oncologic Emergencies. In: Principles and Practice of Pediatric Oncology, 6th, Pizzo, PA, Poplack, DG (Eds), Lippincott Williams and Wilkins, Philadelphia 2011. p.1125.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/2\">",
"      King RM, Telander RL, Smithson WA, et al. Primary mediastinal tumors in children. J Pediatr Surg 1982; 17:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/3\">",
"      Nieto AF, Doty DB. Superior vena cava obstruction: clinical syndrome, etiology, and treatment. Curr Probl Cancer 1986; 10:441.",
"     </a>",
"    </li>",
"    <li>",
"     Lyerly, HK, Sabiston Jr, DC. Primary neoplasms and cysts of the mediastinum. In: Pulmonary diseases and disorders, 2nd ed, Fishman, A (Ed), McGraw-Hill, New York 1988. p.2087.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/5\">",
"      Ingram L, Rivera GK, Shapiro DN. Superior vena cava syndrome associated with childhood malignancy: analysis of 24 cases. Med Pediatr Oncol 1990; 18:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/6\">",
"      Parish JM, Marschke RF Jr, Dines DE, Lee RE. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 1981; 56:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/7\">",
"      Harris GJ, Harman PK, Trinkle JK, Grover FL. Standard biplane roentgenography is highly sensitive in documenting mediastinal masses. Ann Thorac Surg 1987; 44:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/8\">",
"      Batra P, Brown K, Collins JD, et al. Mediastinal masses: magnetic resonance imaging in comparison with computed tomography. J Natl Med Assoc 1991; 83:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/9\">",
"      Narang S, Harte BH, Body SC. Anesthesia for patients with a mediastinal mass. Anesthesiol Clin North America 2001; 19:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/10\">",
"      Bertsch H, Rudoler S, Needle MN, et al. Emergent/urgent therapeutic irradiation in pediatric oncology: patterns of presentation, treatment, and outcome. Med Pediatr Oncol 1998; 30:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/11\">",
"      Loeffler JS, Leopold KA, Recht A, et al. Emergency prebiopsy radiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome. J Clin Oncol 1986; 4:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/12\">",
"      Slinger P, Karsli C. Management of the patient with a large anterior mediastinal mass: recurring myths. Curr Opin Anaesthesiol 2007; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/13\">",
"      Peters M, Beath SV, Puntis JW, John P. Superior vena cava thrombosis causing respiratory obstruction successfully resolved by stenting in a small bowel transplant candidate. Arch Dis Child 2000; 83:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/14\">",
"      Ramdas J, Haymon M, Ward K, et al. Treatment of superior vena cava syndrome with recombinant tissue plasminogen activator in a sickle cell patient undergoing bone marrow transplantation. Pediatr Hematol Oncol 2001; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/15\">",
"      Morales M, Comas V, Trujillo M, Dorta J. Treatment of catheter-induced thrombotic superior vena cava syndrome: a single institution's experience. Support Care Cancer 2000; 8:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/16\">",
"      Lanciego C, Chac&oacute;n JL, Juli&aacute;n A, et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. AJR Am J Roentgenol 2001; 177:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/17\">",
"      Marcy PY, Magn&eacute; N, Bentolila F, et al. Superior vena cava obstruction: is stenting necessary? Support Care Cancer 2001; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/18\">",
"      Oderich GS, Treiman GS, Schneider P, Bhirangi K. Stent placement for treatment of central and peripheral venous obstruction: a long-term multi-institutional experience. J Vasc Surg 2000; 32:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/19\">",
"      Miller JH, McBride K, Little F, Price A. Malignant superior vena cava obstruction: stent placement via the subclavian route. Cardiovasc Intervent Radiol 2000; 23:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/20\">",
"      Ein SH, Stephens CA, Shandling B, Filler RM. Intussusception due to lymphoma. J Pediatr Surg 1986; 21:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/21\">",
"      Sahu S, Saika S, Pai SK, Advani SH. L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1998; 15:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/22\">",
"      Klein SL, Sanford RA, Muhlbauer MS. Pediatric spinal epidural metastases. J Neurosurg 1991; 74:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/23\">",
"      Lewis DW, Packer RJ, Raney B, et al. Incidence, presentation, and outcome of spinal cord disease in children with systemic cancer. Pediatrics 1986; 78:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/24\">",
"      Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol 1998; 16:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/25\">",
"      Rosol TJ, Capen CC. Mechanisms of cancer-induced hypercalcemia. Lab Invest 1992; 67:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/26\">",
"      Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/27\">",
"      Boudailliez BR, Pautard BJ, Sebert JL, et al. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate. Pediatr Nephrol 1990; 4:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/28\">",
"      Kutluk MT, Hazar V, Aky&uuml;z C, et al. Childhood cancer and hypercalcemia: report of a case treated with pamidronate. J Pediatr 1997; 130:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/29\">",
"      Young G, Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in children. Med Pediatr Oncol 1998; 30:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/30\">",
"      Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998; 102:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41129/abstract/31\">",
"      Falcini F, Trapani S, Ermini M, Brandi ML. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 1996; 58:166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14279 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41129=[""].join("\n");
var outline_f40_10_41129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H357921784\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26748618\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35398440\">",
"      INFECTION AND FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26748664\">",
"      CARDIOPULMONARY EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106214698\">",
"      Pleural and pericardial effusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H106214708\">",
"      - Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106215233\">",
"      Hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26748672\">",
"      SVC and SM syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26748715\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26748782\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26748829\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19905530\">",
"      Mediastinal tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19905537\">",
"      Venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26748954\">",
"      ABDOMINAL EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26748961\">",
"      Acute bowel obstruction/intussusception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749009\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749016\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749023\">",
"      Perforation/hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749037\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749044\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749064\">",
"      Typhlitis (Neutropenic enterocolitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197248640\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26749221\">",
"      UROLOGIC/RENAL EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749253\">",
"      Obstructive uropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749292\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749311\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749330\">",
"      Chemotherapy-related complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26749441\">",
"      NEUROLOGIC EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749448\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749475\">",
"      - Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749482\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749501\">",
"      Altered mental status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749549\">",
"      Spinal cord compression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749630\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26749661\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749704\">",
"      Leukostasis and hyperleukocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26749843\">",
"      METABOLIC EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26749851\">",
"      Tumor lysis syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26750049\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26750122\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19904855\">",
"      SIADH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H357921784\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14279\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14279|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?7/53/8030\" title=\"algorithm 1\">",
"      Management of SVCS in children with a mediastinal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14279|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/15/2300\" title=\"table 1\">",
"      Etiology of seizures in children with cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/46/38636\" title=\"table 2\">",
"      Etiology of mental status changes in children with cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/22/4461\" title=\"table 3\">",
"      Initial coma eval and Rx childr",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=related_link\">",
"      Complications of spinal cord irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37896?source=related_link\">",
"      Hemoptysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24276?source=related_link\">",
"      Recovery of renal function after relief of urinary tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19544?source=related_link\">",
"      Treatment and prognosis of coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27125?source=related_link\">",
"      Typhlitis (neutropenic enterocolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_10_41130="Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults";
var content_f40_10_41130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41130/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41130/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41130/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41130/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/10/41130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/10/41130/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/10/41130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression of chronic kidney disease (CKD), as defined by a reduction in the glomerular filtration rate (GFR), occurs at a variable rate, ranging from less than 1 to more than 12",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    per year, depending upon the level of blood pressure control, the degree of proteinuria, the previous rate of GFR decline, and the underlying kidney disease, including diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two major components to slowing the rate of progression of CKD: treatment of the underlying disease, if possible; and treatment of secondary factors that are predictive of progression, such as elevated blood pressure, which is defined differently from that in the general population, and proteinuria. (See",
"    <a class=\"local\" href=\"#H594278\">",
"     'Importance of proteinuria and blood pressure control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical trials evaluating antihypertensive therapy in nondiabetic CKD and our recommendations for choice of therapy as well as treatment goals will be reviewed here. The animal studies that provided the mechanisms and rationale for the clinical trials, the treatment of diabetic nephropathy, and general issues related to the treatment of hypertension in patients with CKD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13206?source=see_link\">",
"     \"Antihypertensive therapy and progression of chronic kidney disease: Experimental studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to slowing the progression of CKD in children is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Slowing chronic kidney disease progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The timing of administration of antihypertensive therapy (ie, morning versus evening dosing) in patients with CKD is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H3128354#H3128354\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Possible benefit from nocturnal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594278\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF PROTEINURIA AND BLOOD PRESSURE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies in animals and humans have shown that progression of a variety of chronic kidney diseases may be largely due to secondary hemodynamic and metabolic factors, rather than the activity of the underlying disorder. The major histologic manifestations of these secondary causes of renal injury are interstitial fibrosis and focal segmental glomerulosclerosis (called secondary FSGS), which are superimposed upon any primary renal injury that may be present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Nephron loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glomerular damage and proteinuria typically occur with progressive chronic kidney disease (CKD), even in primary tubulointerstitial diseases such as chronic pyelonephritis due to reflux nephropathy. Conversely, interstitial fibrosis occurs with progressive CKD, even in the setting of primary glomerular disease.",
"   </p>",
"   <p>",
"    Identification of the factors responsible for secondary injury, such as intraglomerular hypertension, glomerular hypertrophy, and proteinuria greater than 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    is clinically important because they can be treated, slowing disease progression in many patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of antihypertensive therapy in proteinuric nondiabetic CKD have focused on two areas: short-term reduction in protein excretion; and long-term protection against progressive kidney disease. Data are limited on nonproteinuric CKD, defined as CKD associated with urine protein excretion less than 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Among patients with proteinuric CKD, the preferred agents are drugs that block the renin-angiotensin system, such as angiotensin converting enzyme inhibitors and, at least in patients with type 2 diabetes, angiotensin II receptor blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594330\">",
"    <span class=\"h2\">",
"     Importance of proteinuria and the proteinuric response",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CKD, higher degrees of urinary protein excretion are associated with a more rapid decline in glomerular filtration rate (GFR), regardless of the primary cause of the renal disease and the initial GFR (",
"    <a class=\"graphic graphic_figure graphicRef68921 \" href=\"mobipreview.htm?40/46/41701\">",
"     figure 1",
"    </a>",
"    ). In addition to the initial urinary protein excretion, a number of studies have reported correlations between reduction in proteinuria with antihypertensive therapy and slower progression of the renal disease. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'The proteinuric response as a predictor of outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497610\">",
"    <span class=\"h2\">",
"     Importance of blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies show that patients with CKD and a normal blood pressure have better preservation of glomerular filtration rate (GFR) than hypertensive patients. Interventional studies show that lower blood pressure targets (below",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg) are associated with better renal outcomes in patients with proteinuric CKD (defined as urine protein excretion greater than 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H257963561\">",
"     'Effect of goal blood pressure on progression of CKD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECT OF ANTIHYPERTENSIVE DRUGS ON PROTEINURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of antihypertensive drugs on proteinuria varies with drug class. When the blood pressure is controlled, renin-angiotensin system (RAS) inhibitors such as angiotensin converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) are more effective than other antihypertensive drugs in reducing proteinuria and in slowing the rate progression of proteinuric chronic kidney disease (CKD), regardless of etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/3\">",
"     3",
"    </a>",
"    ]. These benefits can be demonstrated even in patients who are not hypertensive and in those with diabetic nephropathy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The generally greater antiproteinuric effect seen with the ACE inhibitors and ARBs is compatible with a greater fall in intraglomerular pressure, which has been demonstrated in animal models of proteinuric CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This effect is mediated in part by dilation of both efferent and afferent glomerular arterioles, rather than only the afferent arterioles as occurs with other classes of antihypertensive drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13206?source=see_link\">",
"     \"Antihypertensive therapy and progression of chronic kidney disease: Experimental studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79962422\">",
"    <span class=\"h2\">",
"     Renin-angiotensin system inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials have identified a preferential benefit of renin-angiotensin system (RAS) inhibitors in reducing proteinuria, compared with other antihypertensive drugs. The rationale behind these studies is the observation that protein excretion varies directly with the intraglomerular pressure in animals with structural glomerular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the reduction in intraglomerular pressure, a variety of other mechanisms may contribute to RAS inhibitor-induced reductions in proteinuria. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct improvement in the permselective properties of the glomerulus by ACE inhibitors, independent of changes in glomerular hemodynamics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. The following findings support this hypothesis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Protein excretion progressively declines over weeks to several months, whereas the hemodynamic effects of ACE inhibition occur rapidly and are then stable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute administration of angiotensin II does not reverse the antiproteinuric effect, despite inducing renal and systemic vasoconstriction, and increasing intraglomerular pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In transgenic rats, overexpression of the angiotensin II receptor (type 1) in glomerular podocytes results in significant proteinuria, foot process effacement, and glomerulosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Angiotensin II reduces the expression of nephrin, a major component of the podocyte slit pore membrane and an important contributor to the glomerular filtration barrier [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/15\">",
"       15",
"      </a>",
"      ]. In contrast, nephrin expression is increased by ACE inhibitor therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACE inhibitors have an antifibrotic effect, which could contribute to the slowing of renal disease progression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H7#H7\">",
"       \"Secondary factors and progression of chronic kidney disease\", section on 'Tubulointerstitial fibrosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The fall in protein excretion induced by RAS inhibitors (and some other antihypertensive drugs described below) may be associated with a reduction in serum lipid levels, which may reduce both the risk of systemic atherosclerosis and the rate of renal disease progression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"       \"Secondary factors and progression of chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ACE inhibitors and ARBs have important side effects in patients with CKD, including the potential to induce hyperkalemia. The risk is low if the glomerular filtration rate is greater than 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    and the initial serum potassium is in the low-normal range, and even lower if a diuretic is also given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/17\">",
"     17",
"    </a>",
"    ]. They can also acutely reduce the glomerular filtration rate, particularly if the patient is hypovolemic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors generally reduce protein excretion by about 30 to 35 percent in patients with nondiabetic or diabetic CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. The antiproteinuric effect is most prominent in patients who are on a low sodium diet or who are treated with diuretics, since relative volume depletion results in greater angiotensin II-dependence of the glomerular microcirculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Importance of salt intake'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is unclear whether the ACE inhibitor dose associated with a maximal antihypertensive effect is the same as that required for an optimal antiproteinuric effect. This issue was addressed in a study of 23 proteinuric patients with nondiabetic renal disease who were given increasing doses of spirapril for maximal antihypertensive effect (median dose of 6",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    as assessed by ambulatory blood pressure monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/24\">",
"     24",
"    </a>",
"    ]. This dose reduced proteinuria from a mean of 2.56 to 1.73",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    An additional increase of spirapril to a supramaximal dose (median dose of 12",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    failed to further decrease either blood pressure or proteinuria. In contrast to these findings, other studies have reported a dissociation between the doses required for optimal antihypertensive and antiproteinuric effects, suggesting that the amounts necessary for these two benefits are likely to vary among patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79962776\">",
"    <span class=\"h3\">",
"     Angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiproteinuric effect of angiotensin II receptor blockers (ARBs) has been demonstrated in patients with diabetic and non-diabetic CKD. Their effect on slowing progression of GFR decline was best demonstrated in diabetic renal disease. It seems likely that they will have a similar renoprotective effect as ACE inhibitors in nondiabetic CKD but supportive data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in humans have found that ARBs are as effective as ACE inhibitors in reducing protein excretion in patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/18,27-29\">",
"     18,27-29",
"    </a>",
"    ]. In a 2008 meta-analysis of 49 randomized trials (mostly small), the reduction in proteinuria at 5 to 12 months was similar with ARBs and ACE inhibitors (ratio of means 1.08, 95% CI 0.96-1.22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with ACE inhibition, there appears to be a dose effect, with greater reduction of proteinuria at higher (even supramaximal) doses in both nondiabetic and diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. In the SMART trial, for example, 269 patients with proteinuria greater than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    despite seven weeks of the maximum approved dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    (16",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    were randomly assigned to candesartan at a dose of 16, 64, or 128",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients who received 128",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    had a significantly greater reduction in proteinuria at 30 weeks compared with those who received 16",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (mean difference 33 percent). The blood pressure was not different between groups. Although hyperkalemia required the withdrawal of 11 patients from the trial, there was no difference in the incidence of hyperkalemia between groups. Further studies of the efficacy and safety are required before such high dose therapy can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79962783\">",
"    <span class=\"h3\">",
"     ACE inhibitor plus ARB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduction in proteinuria appears to be greater when ACE inhibitors are used in combination with ARBs than with either drug alone, although no study has compared combination therapy with doubling the dose of a single agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/18\">",
"     18",
"    </a>",
"    ]. However, it has not been proven that combination therapy improves renal outcomes and adverse effects may be more common. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79963722\">",
"    <span class=\"h2\">",
"     Other antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antihypertensive drugs have a variable effect on protein excretion. These drugs may be used in addition to RAS-inhibitors to further reduce protein excretion but only one trial (AASK) has evaluated the efficacy of such regimens on the rate of disease progression in patients with nondiabetic CKD. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'AASK trial of antihypertensive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79963019\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-dihydropyridine calcium channel blockers, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , have significant antiproteinuric effects in patients with proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/19,34,35\">",
"     19,34,35",
"    </a>",
"    ]. By comparison, the dihydropyridines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , have a variable effect on proteinuria, ranging from an increase to no effect to a fall in protein excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/18,34,36\">",
"     18,34,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences between non-dihydropyridine and dihydropyridine calcium channel blockers were illustrated in a systematic review of 23 studies that adjusted for sample size, study length, and baseline values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/34\">",
"     34",
"    </a>",
"    ]. Based upon an analysis of monotherapy in 510 patients, non-dihydropyridines decreased mean proteinuria by 30 percent and dihydropyridines increased proteinuria by 2 percent (95% CI 10-54% for the differences between the two drug classes). Similar observations were noted when these agents were used in combination with ACE inhibitors or ARBs: despite similar reductions in blood pressure, the mean change in proteinuria was minus 39 and plus 2 percent for non-dihydropyridines and dihydropyridines, respectively.",
"   </p>",
"   <p>",
"    The mechanisms underlying this varied effect on proteinuria may include preferential afferent arteriolar dilatation with dihydropyridines, which allows more of the aortic pressure to be transmitted to the glomerulus, and differential abilities of the non-dihydropyridine and dihydropyridine calcium channel blockers to alter renal autoregulation, the permeability of the glomerulus, and perhaps other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79963826\">",
"    <span class=\"h3\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone antagonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    studied more often than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) further reduce protein excretion when added to an ACE inhibitor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. The following are findings from a meta-analysis that included seven trials in which patients were treated with an ACE inhibitor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARB plus either spironolactone (usually 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significantly greater reduction in proteinuria in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      group (weighted mean difference 800",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      95% CI 330-1270",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"     <li>",
"      The patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      also had a modestly but significantly lower systolic pressure (3.4 mmHg).",
"     </li>",
"     <li>",
"      Short-term changes in eGFR (less than one year of follow-up) were similar with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      and placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, most of these studies did not first maximize the dose of the ACE inhibitor or ARB, and the aldosterone antagonist was associated with an increased risk of hyperkalemia (relative risk 3.1 in the meta-analysis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/37\">",
"     37",
"    </a>",
"    ]. Long-term trials are required to determine if aldosterone antagonists slow the rate of progression of the renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23034975\">",
"    <span class=\"h3\">",
"     Direct renin inhibitors (DRI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct renin inhibitors, like aldosterone antagonists, further reduce proteinuria when added to an ACE inhibitor or ARB. However, this does not appear to translate into clinical benefit. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=see_link&amp;anchor=H13#H13\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\", section on 'Direct renin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Drugs with little or no effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antihypertensive drugs have little or no effect on protein excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. As an example, beta blockers, diuretics, and the alpha-1-blockers (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    ) typically have a lesser antiproteinuric effect than RAS inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. In a 1995 meta-analysis, ACE inhibitors lowered protein excretion by 40 percent compared with 16 percent for beta blockers and 14 percent for other, non-calcium channel blocker antihypertensive drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/19\">",
"     19",
"    </a>",
"    ]. Sympathetic blockers, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/17/32023?source=see_link\">",
"     guanfacine",
"    </a>",
"    , had little effect on protein excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Importance of salt intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with proteinuric CKD, the antiproteinuric effect of RAS inhibitors and non-dihydropyridine calcium channel blockers is impaired with a high salt intake, even when blood pressure control seems appropriate, and is enhanced with salt restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/20,42-48\">",
"     20,42-48",
"    </a>",
"    ]. Similar findings are seen in diabetic nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of diabetic nephropathy\", section on 'Salt intake and proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following examples illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A crossover trial (HONEST) included 52 patients with proteinuric CKD (mean protein excretion 1.6",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      mean creatinine clearance 70",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      all of whom were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/42\">",
"       42",
"      </a>",
"      ]. Four treatments were given in random order, each for six weeks: a low sodium diet with placebo; a low sodium diet with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/4/31815?source=see_link\">",
"       valsartan",
"      </a>",
"      ; a regular sodium diet with placebo; and a regular sodium diet with valsartan. Compared with a regular sodium diet (mean urinary sodium excretion 184",
"      <span class=\"nowrap\">",
"       meq/day),",
"      </span>",
"      a low sodium diet (mean 106",
"      <span class=\"nowrap\">",
"       meq/day)",
"      </span>",
"      decreased mean daily protein excretion to a significantly greater degree than the addition of valsartan (51 versus 21 percent). Addition of valsartan produced a minimal additional reduction in protein excretion beyond a low sodium diet.",
"      <br/>",
"      <br/>",
"      A similar difference was noted with blood pressure control. A low sodium diet reduced the mean systolic pressure from 134 at baseline to 123 mmHg, while the addition of valsartan to either a regular or low sodium diet reduced blood pressure by only 2 to 3 mmHg.",
"     </li>",
"     <li>",
"      A high sodium diet was associated with both a blunting of the proteinuria reduction induced by the ACE inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      and a higher incidence of end-stage renal disease (ESRD) in 500 proteinuric CKD patients enrolled in the REIN and REIN-2 trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/47\">",
"       47",
"      </a>",
"      ]. Patients on a high sodium diet (defined as a 24-hour urinary sodium excretion greater than 250 mmol of sodium [14 grams of salt] per day) had the following adverse outcomes compared with patients on a low sodium diet (defined as a 24 hour urinary sodium excretion less than 125 mmol of sodium [7 grams of salt] per day):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significantly smaller reduction in proteinuria in response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      therapy at three months (20 versus 31 percent). In patients on a lower sodium diet, this initial three-month reduction in proteinuria persisted over the entire four-year study period. However, the initial reduction in proteinuria waned in patients on a high sodium diet, and returned to pre-ramipril levels by the end of the study.",
"     </li>",
"     <li>",
"      A significantly higher incidence of ESRD (32 versus 16 percent). This higher risk of ESRD with a high sodium diet was independent of age, sex, cause of renal disease, and blood pressure. However, the association was attenuated after controlling for changes in proteinuria, suggesting that a high sodium diet mitigated the beneficial effects of the ACE inhibitor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, patients treated with ACE inhibitors or ARBs who do not have a sufficient reduction in protein excretion despite reaching goal blood pressure should be instructed to follow a low salt diet. An assessment of baseline sodium intake can be achieved by obtaining a 24-hour urine collection for sodium and creatinine (creatinine excretion is used to assess the completeness of the collection; the expected normal values are discussed elsewhere). If, after several months, the reduction in protein excretion is less than desired, the 24-hour urine collection can be repeated to determine if a low salt diet has been attained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20663240#H20663240\">",
"     \"Assessment of kidney function\", section on 'Creatinine clearance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a low salt diet is",
"    <strong>",
"     not",
"    </strong>",
"    achieved, administration of a diuretic can enhance the antiproteinuric effect of RAS inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Among patients treated with an ACE inhibitor or ARB, the combination of salt restriction and a diuretic may provide a greater antiproteinuric effect and more blood pressure reduction than either intervention alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of salt intake and salt restriction on blood pressure and the efficacy of antihypertensive medications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link&amp;anchor=H10#H10\">",
"     \"Salt intake, salt restriction, and essential hypertension\", section on 'Effects of dietary sodium restriction on blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFECT OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS ON PROGRESSION OF CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have demonstrated a benefit of antihypertensive therapy with renin-angiotensin system (RAS) inhibitors, mostly angiotensin converting enzyme (ACE) inhibitors, in patients with proteinuric nondiabetic chronic kidney disease (CKD). The renoprotective effect of angiotensin II receptor blockers (ARBs) has been best demonstrated in patients with diabetic nephropathy. It seems likely that they have a similar renoprotective effect as ACE inhibitors in nondiabetic CKD but supportive data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of diabetic nephropathy\", section on 'Renal protection with ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This section will review the trials, and meta-analyses of such trials, that evaluated the efficacy of RAS inhibitors compared with other antihypertensive drugs on the progression of nondiabetic CKD. The trials that evaluated the importance of goal blood pressure in such patients are discussed below. (See",
"    <a class=\"local\" href=\"#H257963561\">",
"     'Effect of goal blood pressure on progression of CKD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12989509\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of randomized trials, including those trials presented below, provide evidence in support of a preferential benefit with ACE inhibitors in proteinuric patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/6,52-57\">",
"     6,52-57",
"    </a>",
"    ]. In a representative meta-analysis, patient-level data were analyzed from 11 randomized, controlled trials that enrolled 1860 nondiabetic patients with CKD; the alternative treatments were other antihypertensive drugs and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/53\">",
"     53",
"    </a>",
"    ]. After statistical adjustments, ACE inhibitor therapy compared with the alternative treatments was associated with significant reductions in the rate of progression to end-stage renal disease (7.4 versus 11.6 percent, relative risk 0.69, 95% CI 0.51-0.94), while that for doubling of the baseline serum creatinine concentration or end-stage renal disease was 13.2 versus 20.5 percent (relative risk 0.70, 95% CI 0.55-0.88). The benefits of ACE inhibitors increased with increasing baseline proteinuria, and were insignificant in patients with proteinuria below 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/55\">",
"     55",
"    </a>",
"    ]. ACE inhibitors were also associated with a significantly larger reduction in blood pressure (4.5 versus 2.3 mmHg), although this may be due to the fact that ACE inhibitors were compared with placebo in five of the trials.",
"   </p>",
"   <p>",
"    The benefits of ACE inhibitors and ARBs on CKD progression in proteinuric patients was confirmed in a meta-analysis of 12 trials that included patients with macroalbuminuria or a combination of macro- and microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/58\">",
"     58",
"    </a>",
"    ]. Compared with other antihypertensive drugs, therapy with ACE inhibitors resulted in a significantly lower incidence of end-stage renal disease (2.6 versus 3.8 percent; relative risk 0.67, 95% CI 0.54-0.84). ARB therapy also reduced the incidence of ESRD compared with other drugs (14 versus 18 percent; relative risk 0.78, 95% CI 0.66-0.90).",
"   </p>",
"   <p>",
"    Additional analyses of these trials from the same research group found that the risk of progression increased with higher baseline systolic pressures above 120 mmHg and increasing proteinuria above 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/6,55\">",
"     6,55",
"    </a>",
"    ]. There is no evidence of benefit from ACE inhibitors or ARBs, or with systolic pressures below 120 mmHg in patients with proteinuria less than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/55\">",
"     55",
"    </a>",
"    ]. Patient outcomes may be worse at systolic pressures below 120 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H149378842\">",
"     'Proteinuria goal'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Blood pressure goal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Benazepril trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     Benazepril",
"    </a>",
"    trial included 583 patients with a variety of chronic nondiabetic kidney diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/61\">",
"     61",
"    </a>",
"    ]. The patients were already in reasonable blood pressure control on a variety of different medications and were then randomly assigned to benazepril or placebo in addition to their usual antihypertensive regimen. At baseline, the mean serum creatinine was 2.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (186",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and mean protein excretion was 1.8",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean attained blood pressure during the trial was significantly lower with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      than with placebo",
"      <span class=\"nowrap\">",
"       (135/84",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       144/88",
"      </span>",
"      mmHg).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       Benazepril",
"      </a>",
"      therapy reduced protein excretion by 25 percent compared with placebo.",
"     </li>",
"     <li>",
"      Progression to the primary endpoint (defined as doubling of the serum creatinine concentration or progression to dialysis) occurred in 31 of 300 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      versus 57 of 283 in the placebo group. The relative risk reduction was 53 percent in the entire group, 71 percent in those with a baseline creatinine clearance above 45",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      and 46 percent in those with a baseline creatinine clearance &le;45",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      There was benefit in patients with chronic glomerular diseases and in the few patients with diabetic nephropathy who were enrolled; the findings were inconclusive in hypertensive nephrosclerosis because too few events occurred. Subsequent trials have shown that ACE inhibitors are associated with a slower rate of decline in glomerular filtration rate in proteinuric patients with essential hypertension and in proteinuric blacks with benign hypertensive nephrosclerosis compared with a beta blocker or calcium channel blocker therapy, despite equivalent degrees of blood pressure control. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'AASK trial of antihypertensive therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       Benazepril",
"      </a>",
"      had no benefit in the 64 patients with polycystic kidney disease or in patients with protein excretion below 1000",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      two settings in which hemodynamically-mediated glomerular disease does not appear to be prominent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link&amp;anchor=H16#H16\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     REIN trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benefit was also noted in a report from the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     Ramipril",
"    </a>",
"    Efficacy In Nephropathy (REIN) trial in which patients with nondiabetic CKD were randomly assigned to ramipril or placebo plus other antihypertensive therapy to attain a diastolic pressure below 90 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/62\">",
"     62",
"    </a>",
"    ]. At baseline, the mean serum creatinine was 2.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (212",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and mean protein excretion was 5.3",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    degree of blood pressure control was the same in both groups. The trial was terminated prematurely in patients excreting more than 3 grams of protein per day because of a significant benefit with ACE inhibition in ameliorating the rate of decline of renal function (0.53 versus 0.88",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per month for placebo).",
"   </p>",
"   <p>",
"    Whether these benefits with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    continued over time in patients excreting more than 3 grams of protein per day was addressed in an observational follow-up study of those initially enrolled in the trial phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/63\">",
"     63",
"    </a>",
"    ]. The rate of decline of renal function and the need for dialysis were the principal outcomes assessed in patients who continued to receive ramipril (51 patients) and in those originally randomized to conventional antihypertensive therapy plus placebo who were switched to ramipril at the beginning of the observational follow-up (46 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/63\">",
"     63",
"    </a>",
"    ]. At 20 months (and at 44 months for the trial phase and observational follow-up combined), the following benefits were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean rate of decline of the glomerular filtration rate (GFR) decreased from 0.44 to 0.10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      for patients originally randomized to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      , and from 0.81 to 0.14",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      for those not originally given ramipril.",
"     </li>",
"     <li>",
"      At the end of the observational follow-up, the group originally randomized to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      had a significantly higher GFR (35.5 versus 23.8",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </li>",
"     <li>",
"      During the entire 44 month period of follow-up (including the trial and observational phases), the incidence of end-stage renal disease was significantly lower in those patients originally assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      compared with those originally assigned to other antihypertensive drugs and then switched to ramipril (19 versus 35 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional follow-up at 60 months found that some patients on continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    therapy even had increased GFR compared with baseline values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-hoc analyses of the REIN trial evaluated the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    in patients with varying degrees of proteinuria and reductions in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      to patients with a GFR less than 45",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and proteinuria between 1.5 and 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      resulted in a significantly lower rate of decline in GFR (-0.31 versus -0.40",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      per month for other therapy) and a decreased incidence of end-stage renal disease (18 versus 52 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal benefits of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      were observed whether the initial (baseline) GFR was within the lowest (11 to 33",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      ), middle (33 to 51",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      ), or highest tertile (51 to 101",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      ). Compared with other drugs, ramipril therapy decreased the rate of GFR decline by 20, 22, and 35 percent, respectively, and the incidence of end-stage renal disease by 33, 37, and 100 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/66\">",
"       66",
"      </a>",
"      ]. The incidence of adverse events was similar across the tertiles and within each tertile for the ramipril and other treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the original and follow-up",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    studies strongly suggest that patients who particularly benefit are those with prominent proteinuria, a finding similar to that noted in other trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/62-65,67,68\">",
"     62-65,67,68",
"    </a>",
"    ]. Significant benefit was also seen in patients with non-nephrotic proteinuria (1.0 to 2.9",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relative benefits from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    also appear to be independent of the initial GFR, but absolute benefits are greater when initiated earlier in the course of renal disease. Given that many patients had significant renal insufficiency (eg, the lowest tertile had a GFR between 11 to 33",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    ), the low incidence of adverse effects with ramipril reflects the exclusion of patients with evidence of hypovolemia and renal artery stenosis, as well as the discontinuation of diuretics prior to initiating ACE inhibitor therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     REIN-2 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lack of renoprotection with a dihydropyridine calcium channel blocker, even when used as add-on therapy to an ACE inhibitor to attain aggressive blood pressure control, was found in the REIN-2 trial of patients with nondiabetic proteinuric CKD (mean baseline GFR 35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and mean proteinuria 2.9",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/69\">",
"     69",
"    </a>",
"    ]. In this trial, 335 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    were randomly assigned to conventional (diastolic pressure less than 90 mmHg) or intensified",
"    <span class=\"nowrap\">",
"     (&lt;130/80",
"    </span>",
"    mmHg) blood pressure control, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    added to attain the lower blood pressure target level. Achieved mean arterial blood pressures were 96.2 and 99.5 mmHg, respectively (corresponding to",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     134/82",
"    </span>",
"    mmHg, respectively).",
"   </p>",
"   <p>",
"    At a median follow-up of 19 months, no significant differences were noted in the proportion of patients who progressed to end-stage renal disease (23 and 20 percent), decline in glomerular filtration rate, and effects on proteinuria.",
"   </p>",
"   <p>",
"    These findings are consistent with previous observations showing that dihydropyridine calcium channel blockers fail to provide renoprotection in patients with nondiabetic proteinuric renal disease, even with further blood pressure reduction from that obtained with fixed doses of ACE inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     AASK trial of antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood pressure of hypertensive African Americans is generally considered to respond better to monotherapy with a calcium channel blocker or a diuretic than an ACE inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/14/15592?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hypertension in blacks\", section on 'Choice of antihypertensive drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The African American Study of Kidney Disease and Hypertension (AASK) trial included 1094 African American patients with hypertensive renal disease. The mean glomerular filtration rate was 46 (range 20 to 65)",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    and mean protein excretion was about 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in men and 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in women. In African Americans with long-standing hypertension, otherwise unexplained progressive CKD with mild proteinuria is almost always associated with histologic changes compatible with hypertensive nephrosclerosis as the sole disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients were randomly assigned to three different antihypertensive drugs and to two different blood pressure goals. The data on goal blood pressure are presented below. (See",
"    <a class=\"local\" href=\"#H371310\">",
"     'AASK trial of goal blood pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients were randomly assigned to treatment with an ACE inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    , 2.5 to 10",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    a calcium channel blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or a beta blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , 50 to 200 mg day); other antihypertensive drugs were added to initial monotherapy to achieve the blood pressure goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/36\">",
"     36",
"    </a>",
"    ]. The primary outcome was the rate of change in glomerular filtration rate (GFR); the main secondary outcome was a composite endpoint of: reduction in GFR of more than 50 percent or more than 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ; end-stage renal disease; or death.",
"   </p>",
"   <p>",
"    The three-year rate of decline in GFR was similar with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    therapy. However, compared with amlodipine, and after adjustment for baseline covariates, ramipril significantly reduced the relative risk of the composite endpoint by 38 percent.",
"   </p>",
"   <p>",
"    However, the relative efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    at three years varied with the degree of proteinuria at baseline:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-third of patients had a urine protein-to-creatinine ratio &gt;0.22 (this protein-to-creatinine ratio is approximately equivalent to 300 mg protein in 24 hours); the mean protein excretion in this subgroup was 1.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in men and 1.2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in women. In these patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      led to a significant 36 percent reduction in the rate of decline in GFR (2.0",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year) and a significant 48 percent reduction in the composite endpoint.",
"     </li>",
"     <li>",
"      In the remaining patients who had a urine protein-to-creatinine ratio of 0.22 or less, there was no significant difference in mean decline in GFR or the composite clinical endpoint among the treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The final results at four years of follow-up showed no difference among the drug groups in reducing the rate of decline of GFR. However, the incidence of the composite endpoint was significantly lower in those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (6.9 versus 8.2 percent per year) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (6.9 versus 8.7 percent per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\", section on 'Choice of antihypertensive agent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After completion of the AASK trial, all of the participants were invited to enroll in a cohort phase during which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    was prescribed to everyone. After five years of additional follow-up during the cohort phase, progression of nephropathy was significantly slowed but not stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Compared with patients with controlled clinic blood pressure or white coat hypertension (ie, hypertension in the doctor&rsquo;s office but not at home), target organ damage (proteinuria, left ventricular hypertrophy) was more likely in patients with elevated blood pressure at night despite good blood pressure control in the office, masked hypertension (which refers to patients with normal office blood pressure who are hypertensive during the day on ambulatory monitoring), isolated ambulatory hypertension, or sustained hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H10#H10\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Nocturnal blood pressure and nondippers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H9#H9\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Masked hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Use in advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A question that is often asked is whether the benefit from ACE inhibitors or ARBs extends to patients with advanced CKD, particularly given the increased risk of hyperkalemia. Stated differently, is there a serum creatinine concentration above which one would not use such therapy? The answer to this question appears to be no, except for truly end-stage disease.",
"   </p>",
"   <p>",
"    The potential value of RAS inhibition in advanced disease was best shown in a Chinese study in which 422 patients with nondiabetic CKD were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    or placebo plus other antihypertensive therapy to attain a systolic and diastolic pressure below 130 and 80 mmHg, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/74\">",
"     74",
"    </a>",
"    ]. Based upon the baseline serum creatinine concentration, patients were divided into two groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group 1 consisted of 141 patients with a serum creatinine concentration between 1.5 to 3.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133 to 265",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      The mean estimated glomerular filtration rate (GFR) and level of proteinuria were 37",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      and 1.6",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Group 2 consisted of 281 patients with a serum creatinine concentration between 3.1 to 5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (274 to 442",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      The mean estimated GFR and proteinuria were approximately 26",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      and 1.6",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients had an eight-week run-in period in which they received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    at 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four weeks; they were closely monitored with weekly measurements of serum creatinine and potassium levels and blood pressure; the dose was increased to 10 mg twice daily if the serum creatinine concentration increased less than 30 percent, the serum potassium remained below 5.6",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and no adverse effects occurred. During this period, 94 patients were excluded from further study because of dry cough, marked changes in renal function, severe hyperkalemia, or poor adherence. Thus, the study group was highly selected.",
"   </p>",
"   <p>",
"    All 104 remaining patients in group 1 received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    (at 10 mg twice daily, since it was deemed unethical to administer placebo), while the 224 patients remaining in group 2 were randomly assigned to benazepril (10 mg twice daily) or placebo. Additional antihypertensive therapy was administered to attain blood pressure goals. The primary endpoint was the composite of doubling of the serum creatinine level, end-stage renal disease (ESRD), or death, while secondary endpoints were change in proteinuria and rate of progression of the renal disease.",
"   </p>",
"   <p>",
"    The following results were noted at a mean follow-up of 3.4 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly fewer group 2 patients (mean GFR of 26",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ) treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      reached the primary endpoint (41 versus 60 percent with placebo), resulting in an overall risk reduction of 43 percent with active therapy. The primary endpoint was reached less often in group 1 patients (22 percent), who had less severe disease and were all treated with benazepril.",
"     </li>",
"     <li>",
"      In group 2 patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      was associated with the following significant benefits: a lower rate of doubling of the serum creatinine concentration and of reaching ESRD by 51 and 40 percent, respectively; a greater reduction of proteinuria (52 versus 20 percent); and a lower rate of decline in GFR (6.8 versus 8.8",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      per year).",
"     </li>",
"     <li>",
"      The extent of proteinuria reduction in patients with protein excretion above 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      correlated significantly with the rate of decline in estimated GFR.",
"     </li>",
"     <li>",
"      The benefits with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      were independent of blood pressure lowering, since the attained blood pressures were comparable in all groups.",
"     </li>",
"     <li>",
"      The incidence of major adverse effects was similar with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      and placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absence of serious hyperkalemia may have resulted from one or more of the following factors: approximately 5 percent of patients in group 2 were excluded from the study because of hyperkalemia during the eight-week run-in period; dietary intake of potassium was likely to be lower than in Western patients; and diuretics were used in more than 80 percent of patients, possibly resulting in increased renal potassium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/75\">",
"     75",
"    </a>",
"    ]. The exclusion of patients with diabetes, which is associated with an increased risk of hypoaldosteronism, may also have contributed to the low incidence of hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link&amp;anchor=H25009310#H25009310\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Diabetes and renal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further evidence in support of benefit from ACE inhibitors in patients with advanced renal failure was found in the REIN trial. As previously mentioned, patients with an initial GFR within the lowest group (11 to 33",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    ) had a 20 percent decrease in the rate of decline in GFR and a 33 percent reduction in the incidence of end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/66\">",
"     66",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H14\">",
"     'REIN trial'",
"    </a>",
"    above). ACE inhibitors also appear to slow the rate of loss of residual renal function being treated with peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Use in elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known if the benefits from renin-angiotensin system (RAS) inhibition in proteinuric CKD extend to patients older than 70 years, because most of the above trials did not include such individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/68\">",
"     68",
"    </a>",
"    ]. This is an important issue since older patients are more likely to have adverse effects from therapy, including acute kidney injury and hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H4#H4\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Reduction in GFR'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older patients with CKD are less likely to have proteinuria, which was required in the most of the RAS inhibition trials cited above. This was demonstrated in an analysis of 1190 National Health and Nutrition Examination Survey (NHANES) participants who were over age 70 and had CKD, which was defined as an estimated GFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    or an albumin-to-creatinine ratio &gt;200",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    of creatinine (approximately 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/68\">",
"     68",
"    </a>",
"    ]. This level of proteinuria was present in only 13 percent. There is no evidence of benefit from RAS inhibition in patients with protein excretion below 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that the great majority of patients over age 70 with CKD would not benefit from RAS inhibition for renoprotection and may have harm from a higher rate of side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/77\">",
"     77",
"    </a>",
"    ]. However, this conclusion does not necessarily apply to patients excreting more than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in whom RAS inhibition may slow disease progression, a benefit that is likely to be greater than any risks. Careful monitoring is warranted. (See",
"    <a class=\"local\" href=\"#H594171\">",
"     'Lack of benefit in nonproteinuric CKD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     The proteinuric response as a predictor of outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nondiabetic CKD, a number of studies, primarily observational post-hoc analyses, and meta-analyses, have reported correlations among the initial degree of urinary protein excretion, reduction in proteinuria with therapy, and decreased progression of renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/6,53,62,65,67,78-83\">",
"     6,53,62,65,67,78-83",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the MDRD study, for each 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      reduction in protein excretion during the first four months, the rate of decline in GFR fell by 0.9 to 1.3",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/81\">",
"       81",
"      </a>",
"      ]. The fall in proteinuria was related to the blood pressure, being more prominent in those with more aggressive blood pressure control.",
"     </li>",
"     <li>",
"      Among patients with protein excretion &ge;3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in the REIN trial, the rate of decline in GFR correlated inversely with the degree of proteinuria reduction and the magnitude of benefit seemed to exceed that expected for the degree of blood pressure lowering [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the benefit associated with proteinuria reduction in patients with CKD, the loss of an initial antiproteinuric response to antihypertensive therapy correlates with an exacerbation of renal dysfunction. This was illustrated in a report of 33 patients with nondiabetic renal disease and an initial antiproteinuric response to ACE inhibition, 14 of whom escaped from this benefit after approximately 19 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/82\">",
"     82",
"    </a>",
"    ]. These patients had a significant increase in the rate of loss of creatinine clearance (+0.05 versus -0.70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per month during the periods of response and escape, respectively).",
"   </p>",
"   <p>",
"    Most studies have found that better renal outcomes are associated with agents that lower both proteinuria and blood pressure. However, no trials have examined &ldquo;goal proteinuria&rdquo; in which different levels of proteinuria reduction were compared.",
"   </p>",
"   <p>",
"    With respect to monitoring proteinuria, we generally monitor protein excretion by repeated measurement of the urine protein-to-creatinine ratio or albumin-to-creatinine ratio in a random urine specimen. These tests are reasonably accurate in detecting changes in protein excretion. (See",
"    <a class=\"local\" href=\"#H149378842\">",
"     'Proteinuria goal'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74959533\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renin-angiotensin system (RAS) inhibition can be associated with a variety of adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to progression of the renal disease, ACE inhibitors and ARBs can cause a decline in renal function and a rise in serum potassium that typically occur one to two weeks after the onset of therapy. Thus, repeat measurement of the serum creatinine and potassium should be obtained during this time frame after the initiation or intensification of therapy.",
"   </p>",
"   <p>",
"    The long-term clinical significance of a modest and stable rise in serum creatinine after the initiation or intensification of RAS inhibitor therapy is uncertain since it is due in part to a reduction in intraglomerular pressure, which is thought to contribute to the slowing of disease progression. An initial elevation in serum creatinine of as much as 30 to 35 percent above baseline that stabilizes within the first two months of therapy is considered acceptable and",
"    <strong>",
"     not",
"    </strong>",
"    a reason to discontinue therapy as long as there is not an excessive fall in blood pressure; the latter is most likely to occur in patients who are volume depleted at the initiation of therapy due, for example, to diuretic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Rather than being an adverse effect, a review of 12 randomized trials found that patients with an acute and stable rise in serum creatinine of up to 30 percent were more likely to have long-term preservation of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Combination of ACE inhibitors and ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials, usually small, have demonstrated that combination ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB",
"    </span>",
"    therapy has a greater antiproteinuric effect than either agent alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/18,86-90\">",
"     18,86-90",
"    </a>",
"    ]. A 2008 meta-analysis of 14 trials in non-diabetic renal disease with 5 to 12 months of follow-up found that combination therapy produced a significant 18 to 25 percent greater reduction in proteinuria compared with monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/18\">",
"     18",
"    </a>",
"    ]. These trials did not attempt to identify a maximum antiproteinuric dose, did not compare combination therapy to high dose monotherapy, and did not assess renal outcomes. Lowering of proteinuria has been a marker for better outcomes in other studies. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'The proteinuric response as a predictor of outcome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One major trial, COOPERATE, suggested significant benefit from combination therapy with an ACE inhibitor and ARB on disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/91\">",
"     91",
"    </a>",
"    ]. However, concerns were raised about the reliability of the data in COOPERATE and the paper has been retracted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. The findings in COOPERATE should",
"    <strong>",
"     not",
"    </strong>",
"    be considered when making decisions about therapy.",
"   </p>",
"   <p>",
"    In addition to lack of proven benefit in proteinuric CKD, combination therapy may have adverse effects as demonstrated in the ONTARGET trial of 25,620 patients with preexisting vascular disease or diabetes. ONTARGET was designed to evaluate the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    , or the combination of both drugs on cardiovascular and renal endpoints during approximately 4.5 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/95\">",
"     95",
"    </a>",
"    ]. A later report from ONTARGET evaluated the effects of combination therapy versus monotherapy in the subset of 5623 patients who, at baseline, had reduced renal function (defined as an estimated glomerular filtration rate less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria (defined as a urine albumin&ndash;to-creatinine ratio greater than 177",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    for men and 248",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    for women, thresholds that roughly correlate with more than 300 mg of albumin on a 24 hour urine collection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations were made among the patients with reduced renal function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy resulted in a small but significant",
"      <strong>",
"       increase",
"      </strong>",
"      in the incidence of end-stage renal disease (ESRD, defined as the need for chronic dialysis) or doubling of the serum creatinine (0.79 versus 0.56 percent per year), but a nonsignificant increase in ESRD alone (0.34 versus 0.27 percent per year).",
"     </li>",
"     <li>",
"      In the group of patients who had both reduced renal function and proteinuria, combination therapy significantly increased the risk of ESRD or doubling of the serum creatinine (4.8 versus 2.8 percent per year), as well as ESRD alone (2.7 versus 1.6 percent per year).",
"     </li>",
"     <li>",
"      Combination therapy did not reduce the risk of cardiovascular disease or death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combination therapy with an ACE inhibitor and ARB compared with monotherapy may also be associated with a slight increase in serum potassium concentration (mean 0.1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in a systematic review of 21 trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H18#H18\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the possible worsening of renal endpoints and lack of proven benefit, we recommend",
"    <strong>",
"     not",
"    </strong>",
"    using combination therapy with ACE inhibitors and ARBs in patients with non-diabetic CKD with the possible exception of IgA nephropathy. (See",
"    <a class=\"local\" href=\"#H149378842\">",
"     'Proteinuria goal'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Proteinuria and blood pressure goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594171\">",
"    <span class=\"h2\">",
"     Lack of benefit in nonproteinuric CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data presented in the preceding section consistently demonstrate the preferential benefits of renin-angiotensin system (RAS) inhibitors in patients with proteinuric chronic kidney disease (CKD). Thus, when trying to slow the progression of nondiabetic CKD, protein excretion above 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    identifies patients who are likely to benefit from antihypertensive therapy with RAS inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/6,55,61,65,98\">",
"     6,55,61,65,98",
"    </a>",
"    ]. However, some experts would set the threshold at 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/3,99\">",
"     3,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, there appears to be no preferential benefit of RAS inhibitors in patients excreting less than 500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    as occurs in most patients with nephrosclerosis and polycystic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\", section on 'Choice of antihypertensive agent'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30582?source=see_link&amp;anchor=H3984957#H3984957\">",
"     \"Hypertension in autosomal dominant polycystic kidney disease\", section on 'Choice of agent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257963561\">",
"    <span class=\"h1\">",
"     EFFECT OF GOAL BLOOD PRESSURE ON PROGRESSION OF CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies showed that patients with chronic kidney disease (CKD) and a diastolic pressure below 90 mmHg had better preservation of glomerular filtration rate (GFR) than hypertensive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/100\">",
"     100",
"    </a>",
"    ]. These observations cannot exclude that patients with normal blood pressure or easily controlled hypertension have less severe underlying disease.",
"   </p>",
"   <p>",
"    This section will review the trials and meta-analyses that evaluated the importance of goal blood pressure on the progression of nondiabetic CKD. The trials that evaluated the efficacy of renin-angiotensin system (RAS) inhibitors compared with other antihypertensive drugs on both proteinuria and disease progression are discussed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Effect of antihypertensive drugs on proteinuria'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The three major trials in adults that evaluated the effect of goal blood pressure on CKD progression primarily included patients who had mild proteinuria (usually less than 1.5",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    However, the results in the MDRD trial suggest that the renal benefit of more aggressive blood control is greatest in patients with higher rates of protein excretion (",
"    <a class=\"graphic graphic_figure graphicRef78190 \" href=\"mobipreview.htm?16/53/17245\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12989758\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2003 meta-analysis from the ACE Inhibition in Progressive Renal Disease study group concluded that a systolic pressure below 130 mmHg was associated with a lower risk of kidney disease progression in patients with a spot urine total protein-to-creatinine ratio &ge;1000",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    (which approximately represents protein excretion of greater than 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, there was no evidence of benefit (adjusted relative risk 1.0) in patients with protein excretion less than 1000",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    A",
"    later systematic review of three trials (MDRD, AASK, and REIN-2) that examined the effects of more versus less aggressive blood pressure lowering in patients with nondiabetic CKD reached a similar conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/101\">",
"     101",
"    </a>",
"    ]. Aggressive blood pressure control was associated with a lower risk of end-stage renal disease or death and a slower rate of decline in glomerular filtration rate in proteinuric patients, but not in patients without proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588167\">",
"    <span class=\"h2\">",
"     MDRD study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from the multicenter Modification of Diet in Renal Disease (MDRD) trial suggest that both the rate of progression and the efficacy of antihypertensive therapy are related to baseline protein excretion, which in turn is a reflection of the severity of glomerular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/98\">",
"     98",
"    </a>",
"    ]. Two groups were compared: one with usual blood pressure control (target mean arterial pressure less than 107 mmHg, which is equivalent to",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg) and one with more aggressive control (target mean arterial pressure less than 92 mmHg, which is equivalent to",
"    <span class=\"nowrap\">",
"     125/75",
"    </span>",
"    mmHg) over a three-year period. The achieved mean arterial pressures were 96 and 91 mmHg (equivalent to",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     125/75",
"    </span>",
"    mmHg, respectively). Almost one-half of the patients were treated with an ACE inhibitor, but its selective efficacy was not assessed.",
"   </p>",
"   <p>",
"    The results in 585 patients with a mean baseline GFR of 39",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and mean urinary protein excretion of 1.1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    can be summarized as follows (",
"    <a class=\"graphic graphic_figure graphicRef78190 \" href=\"mobipreview.htm?16/53/17245\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The loss of GFR was lowest in patients excreting less than 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (2.8 to 3.0",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      year), but no benefit was seen with aggressive blood pressure control.",
"     </li>",
"     <li>",
"      Patients excreting between 1 and 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      had more rapid progression and a modest benefit from aggressive blood pressure control.",
"     </li>",
"     <li>",
"      Patients excreting 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      or more had the fastest rate of progression but a clinically and statistically significant slowing of the rate of progression with aggressive blood pressure control (rate of GFR decline of 10.2 with conventional versus 6.7",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year with aggressive blood pressure control).",
"     </li>",
"     <li>",
"      A secondary analysis suggested that aggressive blood pressure control may be particularly important in blacks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/102\">",
"       102",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11174?source=see_link&amp;anchor=H5#H5\">",
"       \"Hypertensive complications in blacks\", section on 'Goal blood pressure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent study reported the long-term outcomes of patients enrolled in the initial MDRD study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/103\">",
"     103",
"    </a>",
"    ]. After the study was completed in 1993, all participants were passively followed until 2000 for the incidence of renal failure (defined as dialysis or renal transplantation) and all-cause mortality. The mean difference in blood pressure between the two groups during the trial phase was",
"    <span class=\"nowrap\">",
"     7.6/3.8",
"    </span>",
"    mmHg; blood pressure was not measured during passive follow-up. On intention-to-treat analysis, patients in the aggressive control group were significantly less likely to experience renal failure (adjusted hazard ratio 0.68, 95% CI 0.57-0.91), or either renal failure or death (0.77, 95% CI 0.65-91). Renal failure accounted for approximately 90 percent of events and a hazard ratio was not provided for mortality alone.",
"   </p>",
"   <p>",
"    However, a subgroup analysis of this extended follow-up revealed that the benefit from aggressive blood pressure control was only significant in patients with protein excretion exceeding 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (hazard ratio approximately 0.6 to 0.7). The hazard ratio was higher and not significant in patients excreting 300 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or less than 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (hazard ratios of 0.8 and &gt;0.9, respectively). When all patients with protein excretion of 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or less were combined, there was a significant reduction in the hazard ratio for renal failure (0.79, 95% CI 0.63-0.99) but not for the composite outcome of renal failure and death.",
"   </p>",
"   <p>",
"    A substantial limitation of this report was that blood pressure measurements were not available for either group after 1993. As a result, it is unclear if the correlation between improved outcomes and being originally assigned to a lower target blood pressure is related to the maintenance of lower blood pressures during this period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371310\">",
"    <span class=\"h2\">",
"     AASK trial of goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the African American Study of Kidney Disease and Hypertension (AASK) trial, 1094 African-Americans with long-standing hypertension, otherwise unexplained slowly progressive CKD, and usually mild proteinuria (median about 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    were randomly assigned to one of two blood pressure goals:",
"    <span class=\"nowrap\">",
"     125/75",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/36\">",
"     36",
"    </a>",
"    ]. The attained blood pressures were",
"    <span class=\"nowrap\">",
"     128/78",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     141/85",
"    </span>",
"    mmHg. At a mean follow-up of approximately four years, the mean rate of change in glomerular filtration rate and other renal parameters were",
"    <strong>",
"     not different",
"    </strong>",
"    between the two groups.",
"   </p>",
"   <p>",
"    Following completion of the trial phase, participants were invited to continue in a cohort phase of the study, in which the blood pressure target for everyone was",
"    <span class=\"nowrap\">",
"     &lt;130/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/104\">",
"     104",
"    </a>",
"    ]. During the cohort phase, which lasted approximately five years, the mean blood pressure was",
"    <span class=\"nowrap\">",
"     131/78",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     134/78",
"    </span>",
"    mmHg in the intensive control and standard control groups, respectively. The use of ACE inhibitors and ARBs was similar in the two groups. As was observed during the trial phase, there was no difference between groups in the progression of kidney disease (defined as doubling of the serum creatinine, a diagnosis of end-stage renal disease, or death). However, among patients with a baseline urine protein-to-creatinine ratio of greater than 0.22 (corresponding to absolute protein excretion of 300",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    the median 24-hour protein excretion in these patients was approximately 1000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    there was a significant reduction in risk of progression with intensive blood pressure control (hazard ratio 0.73, 95% CI 0.58 to 0.93). In contrast, patients with urine protein-to-creatinine ratios less than 0.22 (median 24-hour protein excretion was 60 mg, ie, nonproteinuric) showed no benefit from intensive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371318\">",
"    <span class=\"h2\">",
"     Polycystic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic kidney disease is typically associated with little or no proteinuria. In a study of 270 patients, for example, mean urinary protein excretion was 260",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with only 48 (18 percent) excreting more than 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/105\">",
"     105",
"    </a>",
"    ]. Patients with more advanced renal dysfunction have more proteinuria (mean about 900",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link&amp;anchor=H4#H4\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized trial, 75 patients with ADPKD, hypertension, and left ventricular hypertrophy were randomly assigned to rigorous (less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg) or standard blood pressure control (135 to",
"    <span class=\"nowrap\">",
"     140/85",
"    </span>",
"    to 90 mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/106\">",
"     106",
"    </a>",
"    ]. The mean attained blood pressures were 90 and 101 mmHg in the rigorous and standard blood pressure groups, respectively (approximately",
"    <span class=\"nowrap\">",
"     116/77",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     133/87",
"    </span>",
"    mmHg in the two groups). At seven years, there was no difference in renal function in the groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30582?source=see_link\">",
"     \"Hypertension in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149378842\">",
"    <span class=\"h1\">",
"     PROTEINURIA GOAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proteinuria goal discussed here applies",
"    <strong>",
"     only",
"    </strong>",
"    to patients with proteinuric chronic kidney disease (CKD). The 2004",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    Clinical Practice Guidelines on hypertension and antihypertensive agents in CKD recommends a goal less than 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    creatinine from the urine protein-to-creatinine ratio on a random urine specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/99\">",
"     99",
"    </a>",
"    ]. However, proteinuria estimated from the urine protein-to-creatinine ratio may be substantially different from daily protein excretion. As an example, creatinine excretion in men under the age of 50 is 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Thus, a nonobese man who weighs 80 kg may excrete 2000 mg of creatinine. In such a patient, a urine protein-to-creatinine ratio of 1000",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    represents protein excretion of approximately 2",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    This would be a suboptimal outcome in patients with IgA nephropathy in whom protein excretion above 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is associated with an adverse renal prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link&amp;anchor=H449899#H449899\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Protein excretion above 1 g/day'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of this potential limitation in using only the urine protein-to-creatinine ratio, we suggest the following approach to measuring and monitoring protein excretion, which takes into account both the greater accuracy of a complete 24-hour urine collection and the greater ease of monitoring with a spot urine specimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 24-hour urine collection should be obtained during the initial evaluation, measuring the excretion of both protein and creatinine. The completeness of the 24-hour urine collection can be estimated from creatinine excretion. Normal values of creatinine excretion vary with muscle mass and, hence, age, gender, and physical activity: in patients under the age of 50 years, 20 to 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      estimated lean body weight in men and 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      estimated lean body weight in women; and, in patients between the ages of 50 and 90 years, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      estimated lean body weight in men). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20663240#H20663240\">",
"       \"Assessment of kidney function\", section on 'Creatinine clearance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the initial 24-hour urine collection seems complete, then the rate of protein excretion is probably an accurate estimate. The urine protein-to-creatinine ratio on this specimen can be related to the total amount of proteinuria, and the urine protein-to-creatinine ratio on a random specimen can subsequently be used to monitor the degree of proteinuria, as long as muscle mass appears stable. If, for example, 24-hour protein excretion is 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in an apparently complete collection and the urine protein-to-creatinine ratio is 2.0, then a ratio below 0.7 would represent goal proteinuria below 1",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest a proteinuria goal of less than 1000",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which is similar to the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    recommendation of 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    creatinine. It may be difficult to attain this goal, particularly in patients with the nephrotic syndrome. In such patients, we suggest a minimum reduction in proteinuria of at least 50 to 60 percent from baseline values",
"    <strong>",
"     plus",
"    </strong>",
"    protein excretion less than 3.5",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    This approach is based upon an observational study in 348 patients with membranous nephropathy and nephrotic syndrome who were treated with renin-angiotensin system (RAS) inhibition and, in some cases, immunosuppressive therapy and were followed for a minimum of one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/107\">",
"     107",
"    </a>",
"    ]. The patients who attained these goals, when compared with patients who reached only one or neither of these goals, had marked reductions in the rate of loss of glomerular filtration rate (0.17 versus 0.86",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per month) and in the incidence of end-stage renal disease (9 versus 29 percent, adjusted hazard ratio 0.17). Subnephrotic proteinuria is also associated with a good renal prognosis in primary focal segmental glomerulosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Importance of attaining remission'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Degree of proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgA nephropathy represents an exception to the above approach since protein excretion above 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and perhaps above 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is associated with a higher risk of disease progression. Thus, the proteinuria goal is less than 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and perhaps less than 500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    if possible, in",
"    <strong>",
"     all",
"    </strong>",
"    patients. The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link&amp;anchor=H449899#H449899\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Protein excretion above 1 g/day'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Proteinuria and blood pressure goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     BLOOD PRESSURE GOAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12989801\">",
"    <span class=\"h2\">",
"     Blood pressure goals depend upon protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to goal blood pressure in patients with nondiabetic CKD is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that blood pressure be lowered to at least less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg in all hypertensive patients.",
"     </li>",
"     <li>",
"      We recommend that blood pressure be lowered to below",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg, rather than below",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg, in patients with proteinuric CKD (defined as protein excretion 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or more).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations are similar to those made by the 2012 international",
"    <a class=\"external\" href=\"file://www.kdigo.org/clinical_practice_guidelines/Hypertension.php\">",
"     KDIGO guidelines for blood pressure management",
"    </a>",
"    in patients with CKD. Lowering the blood pressure to below 120 mmHg systolic is",
"    <strong>",
"     not",
"    </strong>",
"    recommended since patient outcomes may be worse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Our recommendations for goal blood pressure in patients with diabetes mellitus, with or without nephropathy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with established atherosclerotic cardiovascular disease, outcomes are better when the systolic pressure is lowered to below 130 to 135 mmHg. The data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H6#H6\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Placebo-controlled trials with a mean baseline BP less than 140/90 mmHg'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12989966\">",
"    <span class=\"h3\">",
"     Proteinuric patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best data supporting our recommendations for goal blood pressure in proteinuric patients with nondiabetic CKD come from the MDRD trial described above, which assessed the efficacy of both dietary protein restriction and more aggressive blood pressure lowering in patients with CKD. With respect to blood pressure lowering, the achieved mean arterial pressures in the usual and more aggressive blood pressure control arms were 96 and 91 mmHg (equivalent to",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     125/75",
"    </span>",
"    mmHg, respectively). More aggressive blood pressure lowering was associated with slowing of the rate of loss of glomerular filtration rate that was statistically significant only in patients with protein excretion of 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or more at study end (",
"    <a class=\"graphic graphic_figure graphicRef78190 \" href=\"mobipreview.htm?16/53/17245\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H588167\">",
"     'MDRD study'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, both patients excreting &ge;3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and those excreting 1 to 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    had, at long-term follow-up at a mean of 6.2 years, a significantly lower rate of both renal failure, defined as dialysis or renal transplantation, and the combined endpoint of renal failure or all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/10/41130/abstract/103\">",
"     103",
"    </a>",
"    ]. However, it was not clear that this difference was due to the lower target pressure since blood pressure measurements over this period were not available for either group. Nevertheless, these findings are consistent with the meta-analysis cited above, showing benefit from systolic blood pressure lowering to levels below 130 mmHg among CKD patients with protein excretion of 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or higher.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22404873\">",
"    <span class=\"h3\">",
"     Nonproteinuric patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with nonproteinuric (less than 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    nondiabetic CKD, there is no evidence of renal benefit from lowering the blood pressure below the usual goal of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg. (See",
"    <a class=\"local\" href=\"#H257963561\">",
"     'Effect of goal blood pressure on progression of CKD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, in patients with established atherosclerotic cardiovascular disease, outcomes are better when the systolic pressure is lowered to below 130 to 135 mmHg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H6#H6\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Placebo-controlled trials with a mean baseline BP less than 140/90 mmHg'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/62/9188?source=see_link\">",
"       \"Patient information: Medicines for chronic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12989816\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with chronic kidney disease (CKD), higher degrees of urinary protein excretion are associated with a more rapid decline in glomerular filtration rate (GFR), regardless of the primary cause of the renal disease and the initial GFR (",
"      <a class=\"graphic graphic_figure graphicRef68921 \" href=\"mobipreview.htm?40/46/41701\">",
"       figure 1",
"      </a>",
"      ). Observational studies show that patients with CKD and a diastolic pressure below 90 mmHg have better preservation of glomerular filtration rate (GFR) than hypertensive patients. Lower blood pressure targets (below",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg) are associated with better renal outcomes in patients with proteinuric CKD (defined as urine protein excretion greater than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H594330\">",
"       'Importance of proteinuria and the proteinuric response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1497610\">",
"       'Importance of blood pressure control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effect of antihypertensive drugs on proteinuria varies with drug class and salt intake:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When the blood pressure is controlled, renin-angiotensin system (RAS) inhibitors such as angiotensin converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) are more effective than other antihypertensive drugs in reducing proteinuria, regardless of the etiology of CKD. This preferential effect is thought to be due to a reduction in intraglomerular pressure and perhaps other factors. The antiproteinuric effects of ACE inhibitors and ARBs appear to be similar. (See",
"      <a class=\"local\" href=\"#H79962422\">",
"       'Renin-angiotensin system inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The non-dihydropyridine calcium channel blockers",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      have significant antiproteinuric effects in patients with proteinuria. By comparison, the dihydropyridines, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      , have a variable effect on proteinuria, ranging from an increase to no effect to a fall in protein excretion. (See",
"      <a class=\"local\" href=\"#H79963019\">",
"       'Calcium channel blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aldosterone antagonists (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      studied more often than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ) further reduce protein excretion when added to an ACE inhibitor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ARB. (See",
"      <a class=\"local\" href=\"#H79963826\">",
"       'Aldosterone antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other antihypertensive drugs have little or no effect on protein excretion. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Drugs with little or no effect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with proteinuric CKD, the antiproteinuric effect of RAS inhibitors and non-dihydropyridine calcium channel blockers is impaired with a high salt intake, even when blood pressure control seems appropriate, and is enhanced with salt restriction. Similar findings are seen in diabetic nephropathy. If a low salt diet is not achieved, administration of a diuretic can also enhance the antiproteinuric effect of RAS inhibitors. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Importance of salt intake'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple randomized clinical trials in patients with nondiabetic CKD, some with placebo control and some with an active control, have demonstrated a benefit of antihypertensive therapy with RAS inhibitors, mostly angiotensin converting enzyme (ACE) inhibitors, in patients with",
"      <strong>",
"       proteinuric",
"      </strong>",
"      nondiabetic CKD. It seems likely that angiotensin receptor blockers have a similar renoprotective effect as ACE inhibitors in nondiabetic CKD but supportive data are limited. Additional evidence in support of a preferential benefit with ACE inhibitors in proteinuric patients has come from meta-analyses. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-hoc analyses of these and other studies have shown correlations between the reduction in proteinuria with therapy and slower progression of renal disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'The proteinuric response as a predictor of outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When trying to slow the progression of nondiabetic CKD, protein excretion above 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      identifies patients who are most likely to benefit from antihypertensive therapy with RAS inhibitors. In contrast, there appears to be no preferential benefit of RAS inhibitors in patients excreting less than 500",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H594171\">",
"       'Lack of benefit in nonproteinuric CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major trials in adults that evaluated the effect of goal blood pressure on CKD progression suggest that the renal benefit of more aggressive blood control is primarily restricted to patients with higher rates of protein excretion (",
"      <a class=\"graphic graphic_figure graphicRef78190 \" href=\"mobipreview.htm?16/53/17245\">",
"       figure 2",
"      </a>",
"      ). Meta-analyses of randomized trials support this conclusion. (See",
"      <a class=\"local\" href=\"#H257963561\">",
"       'Effect of goal blood pressure on progression of CKD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12989828\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with proteinuric (defined as protein excretion above 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      nondiabetic CKD, we recommend a renin-angiotensin system (RAS) inhibitor as first-line therapy for the treatment of hypertension (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In hypertensive patients with nonproteinuric nondiabetic CKD who have edema, we suggest initiation of a diuretic as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If there is",
"      <strong>",
"       no",
"      </strong>",
"      edema, we suggest RAS inhibitors as first line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H2001798#H2001798\">",
"       \"Overview of hypertension in acute and chronic kidney disease\", section on 'Sequence of antihypertensive therapy in nonproteinuric CKD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with proteinuric nondiabetic CKD, we suggest a proteinuria goal of less than 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients who are initially nephrotic and in whom this goal is unobtainable, we attempt to achieve a minimum reduction in proteinuria of at least 50 to 60 percent from baseline values plus protein excretion less than 3.5",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H149378842\">",
"       'Proteinuria goal'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because of potential limitations in using only the urine protein-to-creatinine ratio to follow protein excretion, we obtain a 24-hour urine for protein and creatinine excretion during the initial evaluation, and then compare the protein-to-creatinine ratio to the 24-hour protein excretion. This allows the subsequent use of spot urine protein-to-creatinine ratios to more accurately estimate the degree of proteinuria.(See",
"      <a class=\"local\" href=\"#H149378842\">",
"       'Proteinuria goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with proteinuric nondiabetic CKD, we recommend a blood pressure goal of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg rather than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H257963561\">",
"       'Effect of goal blood pressure on progression of CKD'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In patients with nonproteinuric nondiabetic CKD, we recommend a blood pressure goal of at least less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In patients with established atherosclerotic cardiovascular disease, outcomes are better when the systolic pressure is lowered to below 130 to 135 mmHg. The data are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H6#H6\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Placebo-controlled trials with a mean baseline BP less than 140/90 mmHg'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In most patients with nondiabetic CKD, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      using combination therapy with ACE inhibitors and ARBs (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The potential use of this combination in patients with IgA nephropathy is discussed separately. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Combination of ACE inhibitors and ARBs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H18#H18\">",
"       \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Combination of ACE inhibitors and ARBs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment and prognosis of IgA nephropathy\", section on 'Combination of ACE inhibitor and ARB'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/1\">",
"      Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/2\">",
"      Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/3\">",
"      Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/4\">",
"      Weir MR. Progressive renal and cardiovascular disease: optimal treatment strategies. Kidney Int 2002; 62:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/5\">",
"      Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/6\">",
"      Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/7\">",
"      Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/8\">",
"      Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994; 45:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/9\">",
"      Yoshioka T, Rennke HG, Salant DJ, et al. Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: a study in early passive Heymann nephritis. Circ Res 1987; 61:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/10\">",
"      Remuzzi A, Puntorieri S, Battaglia C, et al. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/11\">",
"      Remuzzi A, Perticucci E, Ruggenenti P, et al. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/12\">",
"      Gansevoort RT, de Zeeuw D, de Jong PE. Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993; 44:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/13\">",
"      Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. Kidney Int 1991; 40:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/14\">",
"      Hoffmann S, Podlich D, H&auml;hnel B, et al. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004; 15:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/15\">",
"      Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/16\">",
"      Langham RG, Kelly DJ, Cox AJ, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002; 45:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/17\">",
"      Weinberg JM, Appel LJ, Bakris G, et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009; 169:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/18\">",
"      Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/19\">",
"      Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/20\">",
"      Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/21\">",
"      Apperloo AJ, de Zeeuw D, Sluiter HE, de Jong PE. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ 1991; 303:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/22\">",
"      Rosenberg ME, Hostetter TH. Comparative effects of antihypertensives on proteinuria: angiotensin-converting enzyme inhibitor versus alpha 1-antagonist. Am J Kidney Dis 1991; 18:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/23\">",
"      Bedogna V, Valvo E, Casagrande P, et al. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int 1990; 38:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/24\">",
"      Haas M, Leko-Mohr Z, Erler C, Mayer G. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002; 40:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/25\">",
"      Navis G, Kramer AB, de Jong PE. High-dose ACE inhibition: can it improve renoprotection? Am J Kidney Dis 2002; 40:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/26\">",
"      Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/27\">",
"      Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002; 13:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/28\">",
"      Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/29\">",
"      Remuzzi A, Perico N, Sangalli F, et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999; 276:F457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/30\">",
"      Schmieder RE, Klingbeil AU, Fleischmann EH, et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005; 16:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/31\">",
"      Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/32\">",
"      Aranda P, Segura J, Ruilope LM, et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005; 46:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/33\">",
"      Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/34\">",
"      Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/35\">",
"      Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998; 9:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/36\">",
"      Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/37\">",
"      Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/38\">",
"      Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/39\">",
"      Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/40\">",
"      Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/41\">",
"      Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/42\">",
"      Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/43\">",
"      Gansevoort RT, Wapstra FH, Weening JJ, et al. Sodium depletion enhances the antiproteinuric effect of ACE inhibition in established experimental nephrosis. Nephron 1992; 60:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/44\">",
"      Mishra SI, Jones-Burton C, Fink JC, et al. Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep 2005; 7:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/45\">",
"      Bakris GL, Weir MR. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens 1996; 9:200S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/46\">",
"      Barnes CE, Wilmer WA, Hernandez RA Jr, et al. Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated. Nephron Clin Pract 2011; 119:c145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/47\">",
"      Vegter S, Perna A, Postma MJ, et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/48\">",
"      Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/49\">",
"      Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/50\">",
"      Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/51\">",
"      Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/52\">",
"      Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012; 156:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/53\">",
"      Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/54\">",
"      Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/55\">",
"      Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/56\">",
"      Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/57\">",
"      Sharma P, Blackburn RC, Parke CL, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev 2011; :CD007751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/58\">",
"      Maione A, Navaneethan SD, Graziano G, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2011; 26:2827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/59\">",
"      Weiner DE, Tighiouart H, Levey AS, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007; 18:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/60\">",
"      Mulrow CD, Townsend RR. Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: proteinuria and blood pressure levels? Ann Intern Med 2003; 139:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/61\">",
"      Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/62\">",
"      Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/63\">",
"      Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/64\">",
"      Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999; 10:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/65\">",
"      Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/66\">",
"      Ruggenenti P, Perna A, Remuzzi G, Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001; 12:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/67\">",
"      Ruggenenti P, Perna A, Gherardi G, et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000; 35:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/68\">",
"      O'Hare AM, Kaufman JS, Covinsky KE, et al. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med 2009; 150:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/69\">",
"      Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/70\">",
"      Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/71\">",
"      Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/72\">",
"      Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008; 168:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/73\">",
"      Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009; 53:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/74\">",
"      Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/75\">",
"      Hebert LA. Optimizing ACE-inhibitor therapy for chronic kidney disease. N Engl J Med 2006; 354:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/76\">",
"      Li PK, Chow KM, Wong TY, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/77\">",
"      Sarafidis PA, Bakris GL. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med 2009; 150:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/78\">",
"      de Jong PE, Anderson S, de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome? J Am Soc Nephrol 1993; 3:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/79\">",
"      Praga M, Hern&aacute;ndez E, Montoyo C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992; 20:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/80\">",
"      Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/81\">",
"      Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/82\">",
"      Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/83\">",
"      Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/84\">",
"      Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/85\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/86\">",
"      Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/87\">",
"      Kincaid-Smith P, Fairley KF, Packham D. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol Dial Transplant 2004; 19:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/88\">",
"      Laverman GD, Navis G, Henning RH, et al. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/89\">",
"      Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/90\">",
"      Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/91\">",
"      Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/92\">",
"      Kunz R, Wolbers M, Glass T, Mann JF. The COOPERATE trial: a letter of concern. Lancet 2008; 371:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/93\">",
"      Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol 2006; 26:629, 632; author reply 629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/94\">",
"      Retraction--Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009; 374:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/95\">",
"      ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/96\">",
"      Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/97\">",
"      MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/98\">",
"      Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877.",
"     </a>",
"    </li>",
"    <li>",
"     K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43:5(Suppl 1):S1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/100\">",
"      Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990; 37:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/101\">",
"      Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011; 154:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/102\">",
"      Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997; 30:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/103\">",
"      Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/104\">",
"      Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/105\">",
"      Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/106\">",
"      Schrier R, McFann K, Johnson A, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002; 13:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/10/41130/abstract/107\">",
"      Troyanov S, Wall CA, Miller JA, et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66:1199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7169 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-2522EA1FE6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41130=[""].join("\n");
var outline_f40_10_41130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H594278\">",
"      IMPORTANCE OF PROTEINURIA AND BLOOD PRESSURE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H594330\">",
"      Importance of proteinuria and the proteinuric response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497610\">",
"      Importance of blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECT OF ANTIHYPERTENSIVE DRUGS ON PROTEINURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79962422\">",
"      Renin-angiotensin system inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79962776\">",
"      - Angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79962783\">",
"      - ACE inhibitor plus ARB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79963722\">",
"      Other antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79963019\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79963826\">",
"      - Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23034975\">",
"      - Direct renin inhibitors (DRI)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Drugs with little or no effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Importance of salt intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFECT OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS ON PROGRESSION OF CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12989509\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Benazepril trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      REIN trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - REIN-2 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AASK trial of antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Use in advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Use in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      The proteinuric response as a predictor of outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74959533\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Combination of ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H594171\">",
"      Lack of benefit in nonproteinuric CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257963561\">",
"      EFFECT OF GOAL BLOOD PRESSURE ON PROGRESSION OF CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12989758\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H588167\">",
"      MDRD study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371310\">",
"      AASK trial of goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371318\">",
"      Polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H149378842\">",
"      PROTEINURIA GOAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      BLOOD PRESSURE GOAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12989801\">",
"      Blood pressure goals depend upon protein excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12989966\">",
"      - Proteinuric patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22404873\">",
"      - Nonproteinuric patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12989816\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12989828\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7169\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7169|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/46/41701\" title=\"figure 1\">",
"      Relative risks of major complications of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/53/17245\" title=\"figure 2\">",
"      Aggressive BP reduction in CRF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13206?source=related_link\">",
"      Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=related_link\">",
"      Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30582?source=related_link\">",
"      Hypertension in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11174?source=related_link\">",
"      Hypertensive complications in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/62/9188?source=related_link\">",
"      Patient information: Medicines for chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_10_41131="Common x-ray views by fracture location";
var content_f40_10_41131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common radiographic views for identifying fractures by location",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Anatomic region",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plain radiograph fracture views",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wrist",
"       </td>",
"       <td>",
"        <p>",
"         AP, lateral",
"        </p>",
"        <p>",
"         Oblique: fracture suspected but AP and lateral negative*",
"        </p>",
"        Scaphoid: scaphoid fracture suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elbow",
"       </td>",
"       <td>",
"        AP, lateral, oblique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shoulder",
"       </td>",
"       <td>",
"        AP, scapular Y, axillary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knee",
"       </td>",
"       <td>",
"        <p>",
"         AP, lateral, oblique",
"         <sup>",
"          &bull;",
"         </sup>",
"         (internal or external rotated)",
"        </p>",
"        Sunrise (axial, tangential): patellar injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foot",
"       </td>",
"       <td>",
"        <p>",
"         AP, lateral",
"        </p>",
"        Oblique: if fracture seen on AP or lateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tibia, femur, forearm",
"       </td>",
"       <td>",
"        AP, lateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ankle",
"       </td>",
"       <td>",
"        AP, lateral, and mortise",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AP: anterior-posterior.",
"     <br/>",
"     * Provides view of the scaphoid-trapezoid-trapezium articulation.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Provides a different projection of the femoral condyles and tibial tuberosities as well as a cleaner view of the medial and lateral margins of the patella.",
"     <br/>",
"     &Delta; Mortise view requires 10 to 20 degrees of internal rotation and allows the tibia and fibula to be viewed without superimposition.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41131=[""].join("\n");
var outline_f40_10_41131=null;
var title_f40_10_41132="Renal dosing of cephalosporins";
var content_f40_10_41132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dose of parenteral cephalosporins with adjustments for renal failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Glomerular filtration rate (GFR) mL/min*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Removal by dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &gt;50 (normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-50",
"       </td>",
"       <td class=\"subtitle2\">",
"        &lt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        1-2 g Q 8 h",
"       </td>",
"       <td>",
"        0.5-1 g Q 12 h",
"       </td>",
"       <td>",
"        0.5-1 g Q 24 h",
"       </td>",
"       <td>",
"        Yes (HD), No (PD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefuroxime",
"       </td>",
"       <td>",
"        0.75-1.5 g Q 6-8 h",
"       </td>",
"       <td>",
"        0.75-1.5 g Q 8-12 h",
"       </td>",
"       <td>",
"        0.75 g Q 24 h",
"       </td>",
"       <td>",
"        Yes (HD, PD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefoxitin",
"       </td>",
"       <td>",
"        1-2 g Q 4-6 h",
"       </td>",
"       <td>",
"        1-2 g Q 8-12 h",
"       </td>",
"       <td>",
"        0.5-1 g Q 24 h",
"       </td>",
"       <td>",
"        Yes (HD), No (PD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotetan",
"       </td>",
"       <td>",
"        1-2 g Q 12 h",
"       </td>",
"       <td>",
"        1-2 g Q 24 h",
"       </td>",
"       <td>",
"        1-2 g Q 48 h",
"       </td>",
"       <td>",
"        Yes (HD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotaxime",
"       </td>",
"       <td>",
"        1-2 g Q 6 h",
"       </td>",
"       <td>",
"        1-2 g Q 8-12 h",
"       </td>",
"       <td>",
"        1-2 g Q 12-24 h",
"       </td>",
"       <td>",
"        Yes (HD), No (PD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftizoxime",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1-2 g Q 6-8 h",
"       </td>",
"       <td>",
"        0.25-1 g Q 8-12 h",
"       </td>",
"       <td>",
"        0.25-1 g Q 24 h",
"       </td>",
"       <td>",
"        Yes (HD), No (PD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        1-2 g Q 12-24 h",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        No (HD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftazidime",
"       </td>",
"       <td>",
"        1-2 g Q 8 h",
"       </td>",
"       <td>",
"        1-2 g Q 12-24 h",
"       </td>",
"       <td>",
"        0.5-1 g Q 24-48 h",
"       </td>",
"       <td>",
"        Yes (HD, PD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefepime",
"       </td>",
"       <td>",
"        1-2 g Q 8-12 h",
"       </td>",
"       <td>",
"        0.5-2 g Q 12-24 h",
"       </td>",
"       <td>",
"        0.25-1 g Q 24 h",
"       </td>",
"       <td>",
"        Yes (HD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftaroline",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        600 mg Q 12 h",
"       </td>",
"       <td>",
"        300-400 mg Q 12 h",
"       </td>",
"       <td>",
"        200-400 mg Q 12 h",
"       </td>",
"       <td>",
"        Yes (HD)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    HD: hemodialysis; PD: peritoneal dialysis; NC: no change.",
"    <div class=\"footnotes\">",
"     * Usual adult dosing and renal adjustments shown are for moderate to severe infections. For specific dosing recommendations, see related disease treatment topics and Lexi-Comp drug information included with UpToDate.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Not available in the United States or Canada.",
"      <br>",
"       &Delta; 1 hour infusion.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41132=[""].join("\n");
var outline_f40_10_41132=null;
var title_f40_10_41133="Management of plasma lactates";
var content_f40_10_41133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for the management of elevated plasma lactates",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 325px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kees Brinkman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41133=[""].join("\n");
var outline_f40_10_41133=null;
var title_f40_10_41134="Audiograms in Cogans I";
var content_f40_10_41134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serial pure tone audiograms in Cogan's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 144px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three audiograms are presented from a patient with Cogan's syndrome and hearing loss: A) Two months after the onset of Cogan's syndrome during initial corticosteroid therapy; B) Four and one-half years into disease course while taking alternate-day corticosteroid therapy; C) Eight years after onset of disease with stable to improved hearing acuity. _-----_, right ear; X-----X, left ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Haynes, BF, Kaiser-Kupfer, MI, Mason, P, et al. Corgan syndrome: Studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine 1980; 59:426. Copyright &copy;1980 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41134=[""].join("\n");
var outline_f40_10_41134=null;
var title_f40_10_41135="Somatic recombination in TCR genes";
var content_f40_10_41135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 643px\">",
"   <div class=\"ttl\">",
"    Somatic recombination in the T cell receptor (TCR) &alpha; and &beta; genes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 623px; height: 551px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Germline and mature T&nbsp;cell forms of the TCR alpha chain. The somatic rearrangement depicted results in a V&alpha;4 J&alpha;60 C&alpha; TCR &alpha; chain. B) Germline and mature T cell&nbsp;forms of the TCR beta chain. Somatic rearrangements depicted generate beta chains that use different C&beta; exons. For the purpose of illustration, the C&beta;1 TCR &beta; chain depicted is V&beta;51 D&beta;1 J&beta;1.5 C&beta;1, and the C&beta;2 chain is V&beta;1 D&beta;2 J&beta;2.1 C&beta;2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Johnson, RM, Brown, EJ. Cell-Mediated Immunity in Host Defense against Infectious Diseases. In: Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 5th Ed, Vol 1, Mandell, GL, Bennett, JE, Dolin, R (Eds), Churchill Livingston, Philadelphia 2000. p.121.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_10_41135=[""].join("\n");
var outline_f40_10_41135=null;
               